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ABSTRACT

ASSESSMENT OF MOLECULAR ACTION OF DIRECT GATING AND
ALLOSTERIC MODULATORY EFFECTS OF MEPROBAMATE (MILTOWN®)
ON GABAA RECEPTORS
Manish Kumar
Meprobamate (tradenames Miltown, Equanil) is a schedule IV anxiolytic and the primary
metabolite of the muscle relaxant carisoprodol.

Meprobamate modulates GABA A (-

aminobutyric acid type A) receptors, and has been described as having barbiturate-like activity.
A thorough understanding of its mechanism remains ill-defined, however. To gain insight into
its actions, we have conducted a series of studies using recombinant GABAA receptors. In
xz GABAA receptors (where x = 1-6 and z = 1-3), the ability to enhance GABA-mediated
current was evident for all  subunit isoforms, with the largest effect observed in 5-expressing
receptors. Direct gating was comparable with all  subunits, although the effect was attenuated
in α3-expressing receptors. Allosteric potentiating and direct gating effects were comparable
in 112 and 122 receptors, whereas allosteric effects were enhanced in 12 compared
to 122 receptors. In “extrasynaptic” GABAA receptors (α1β3δ and α4β3δ receptors),
meprobamate allosterically enhanced both EC20 and saturating GABA currents, and directly
activated these receptors with an efficacy comparable to that of GABA. Bemegride, which
antagonizes effects of pentobarbital, attenuated direct gating effects of meprobamate. Whereas
pentobarbital directly gated homomeric β3 receptors, meprobamate did not, and instead
blocked the spontaneously open current present in these receptors. In wild type homomeric ρ1

receptors, both pentobarbital and meprobamate were ineffective in direct gating; a mutation
(W328M) previously shown to confer sensitivity to pentobarbital, did not confer sensitivity to
meprobamate. Our results provide additional insight into the actions of meprobamate and
parent therapeutic agents such as Carisoprodol as well as possible domains involved in the
direct gating actions of the ligands including transmembrane domains TM4. Further, using sitedirected-mutagenesis and whole cell patch clamp electrophysiology in transiently transfected
HEK293 cells, we examined the role of GABAA receptor α-subunit transmembrane domain 4
(TM4) and transmembrane domain 2 (TM2) amino acids in direct gating, and inhibitory actions
of meprobamate. Mutation of α3 valine at position 440 to leucine (present in the equivalent
position in the α1 subunit) increased the direct gating potency and efficacy of meprobamate.
In R-α1β2 heteromeric GABAA receptor, both pentobarbital and carisoprodol had inhibitory
effect for allosteric modulatory action at higher concentrations. Meprobamate did not have an
inhibitory effect at the concentrations tested. T6’F mutation of the β2-subunit abolished the
inhibition of carisoprodol but not of pentobarbital. Thus, our studies provide further insight
into actions of meprobamate, its parent drug carisoprodol and their comparison to barbiturate
pentobarbital.
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CHAPTER I
INTRODUCTION
MEPROBAMATE
History
Meprobamate was the first drug to be marketed specifically as an anxiolytic drug, that
is, capable of allaying anxiety and related conditions, without inducing sedation or sleep.
Development of meprobamate is attributed to some serendipitous observations during the
course of development of new preservatives, after discovery of penicillin. During the course
of a search for compound to prevent enzymatic destruction of penicillin by penicillinase
producing gram-negative bacteria, normally present in the air, a compound mephenesin was
found to have reversible tranquilizing and muscle relaxing properties (Berger et al., 1946).
Although later a powder form of penicillin made obsolete the use of preservatives, some
interesting properties observed with these α-substituted esters of glycerol, created a lot of
attention. As stated earlier, mephenesin possessed tranquilizing and at high doses, sedative and
muscle relaxant properties. Initial excitatory effect, associated with barbiturate use was absent,
showing a lack of central action. For the muscle relaxant properties, diaphragm muscle was
last to get affected, causing the respiratory paralysis to appear last as a lethal side effect and at
a very high dose. There was a large gap between dose for paralysis of other muscles and
diaphragmatic muscle (Berger, 1947). However, curare, a widely used muscle relaxant of the
day as an adjuvant to anesthetics, had respiratory paralysis as a major side effect (Delahanty et
al., 2011; Chen et al., 2014). In addition, mephenesin possessed a unique anticonvulsant action.
Strychnine-induced convulsions (convulsions induced via actions at spinal cord) were inhibited
by tranquilizing doses of mephenesin while hexobarbitone, a barbiturate, was unable to prevent
these. Leptazol induced convulsions (convulsions induced via actions on midbrain), were
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inhibited by hexobarbitone, but required a very high dose of mephenesin. Above effects show
the effect of mephenesin at spinal cord level rather than at the midbrain level. This also
explained the initial missing euphoric and exciting action associated with the use of
mephenesin (associated with a central action), present with the use of barbiturates. However,
its use as such was limited by its three major drawbacks—mephenesin was quickly metabolized
to inactive products leading to a very short duration of action, greater effect on the spinal cord
than on supra-spinal structures and a weak action, so large doses were required (Berger, 1947).
Mephenesin was quickly metabolized via oxidation of its terminal hydroxyl group leading to
the formation of inactive metabolites. Blocking the oxidation of the terminal hydroxyl group
would be a major mechanism for extended action of mephenesin. After some trial and error,
carbamate esters of 1, 3-propane diols were prepared which had longer duration of action and
stronger muscle relaxant properties. By the late 1950s meprobamate was the most widely
prescribed drug in the United States and in many other countries. It retained its lead until
diazepam, the second drug from the benzodiazepine series, was introduced into clinical use in
late 1960 (Greenblatt et al., 1974).
Within 2 years of introduction of meprobamate, cases of its abuse and withdrawal after
long term use were reported (Boyd et al., 1958). By 1970 it was listed as a controlled substance,
in USA market, after it was discovered to cause physical and psychological dependence. While
meprobamate was made a controlled substance, drugs metabolized to meprobamate are widely
used and abused and are associated with serious side effects. One such drug carisoprodol,
would be discussed in the later sections of this dissertation.
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Fig 1. Chemical structure of meprobamate and mephenesin
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Chemistry and Physiological Effects of Meprobamate
Meprobamate (Miltown by wallace laboratories and Equanil by Wyeth Laboratories),
chemically, is 2-methyl-2-npropyl- 1, 3-propanediol dicarbamate. First synthesized in 1950 by
Ludwig and Piech (1951), meprobamate has the following physical properties: It is a white
crystalline powder with a characteristic bitter taste and faint odor. It melts without
decomposition at 104-106°C. It is soluble in water to the extent of 0.34 per cent at 20°C and
0.79 per cent at 37°C, but is readily soluble in most organic solvents. It is unaffected by dilute
acid and alkali and thus is not broken down in gastric or intestinal juices (Berger, 1954).
Meprobamate when applied to mice, lead to a sedative action accompanied by loss of
righting reflex. Unlike barbiturates, loss of righting reflex associated with the use of
meprobamate is unaccompanied by any sign of excitability. Common signs of excitability like
aimless running, arching and stretching of back and hind limbs, licking of paws, are present
during induction of barbiturates, while absent even at paralyzing doses of meprobamate.
Recovery is spontaneous and complete. Although mephenesin too had similar anesthetic
action, meprobamate had longer periods of induction and duration and is also effective orally
(Berger, 1954).
Monkeys exposed to 200 mg/kg meprobamate, calmed down and became easier to
control. They became easier to pet and easily had their food. There were no signs of agitation
or excitement. This stage lasted for 5-6 hours. At 400 mg/kg dose, there was a complete flaccid
paralysis that lasted for 7 hours. At higher doses there was longer duration of action. Even at
these higher doses respiration and heart beat were normal and the monkeys recovered almost
completely without any immediate or later ill effects (Berger, 1954).
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Dogs exposed to high dose of meprobamate for a long duration (sub-acute, 60-75
days), did not show any hematological abnormality or abnormalities in kidney function tests.
Autopsy reports also did not show ill effects in viscera of kidney, liver, stomach, small
intestine, bladder or adrenal glands. Mice exposed to very high doses for a very long time
period (chronic, 12-15 months) also did not show signs of toxicity, except for decreased weight
gain (Berger, 1954).
Meprobamate was also effective in preventing pentylenetetrazole, strychnine and
electroshock mediated convulsions and death in mice (Berger, 1954).
A search for separation of muscle relaxant properties of meprobamate with its
tranquilizing properties led to invention of N-isopropyl-2-methyl-npropyl-1,3-propanediol
dicarbamate or carisoprodol which differed from meprobamate in having an iso-propyl group
in place of hydrogen atom in one of the carbomyl nitrogens (Berger 1959). Although minor,
the difference in structure produced surprisingly different pharmacological and functional
properties in carisoprodol.
In electro encephalic recordings in cats and rabbits, meprobamate did not have any
effect in brain wave patterns (Gangloff, 1959). Carisoprodol in similar doses, produced an
increase in amplitude and a decrease in frequency in the cortical and sub cortical regions
(Berger et al., 1960). The characteristic spindling of electro encephalic recordings of
barbiturates was also missing with that of both carisoprodol and meprobamate. Larger doses
of carisoprodol caused a progressive slowing of frequency and an increase in amplitude until
40-60mg/kg dose. Still higher doses caused greatly reduced activity and longer stretches of
electric silence (Berger et al., 1960). A remarkable property of carisoprodol, at lower doses (5
– 10 mg/kg), as we see above is the changes in the brain wave pattern, unaccompanied by
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behavioral changes. In this respect carisoprodol resembled atropine, the anti-cholinergic agent,
which also made changes in the brain wave pattern unaccompanied by behavioral changes
(Longo, 1956; Bradley et al., 1957). However at higher doses, while carisoprodol caused
muscle relaxation, paralysis and a generalized central nervous system depression, atropine lead
to an excitement. On account of the above similarity, when carisoprodol was explored for
peripheral anticholinergic actions, it was found to have none. Convulsions by convulsive
discharges set up in limbic system by electric stimulation, were prevented by meprobamate,
mephenesin and barbiturates, but not by carisoprodol. This was a strange finding considering
more similarity in the structure of meprobamate and carisoprodol compared to meprobamate
and mephenesin. This lack of action of carisoprodol in the limbic system fits with clinical
finding of lack of tranquilising action with carisorpodol (Berger et al., 1960).
Felbamate

Felabamte (2-phenyl-1,3-propanediol dicarbamate) was prescribed as an anti-epileptic
drug prescribed in adult (Absence seizure), and childhood epilepsy (Lenaux-Gastaut
syndrome). However, fatal cases of aplastic anemia and hepatotoxicity has precluded its use as
an anti-epileptic agent. Thus its use has been confined to refractory cased of epilepsy and
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Lenaux-gastaut syndrome. However recent clinical trials have shown it to be safe, well
tolerated and effective in various types of epilepsy syndromes (Shah et al., 2016).
Felbamate has been known to act via activation of GABAA receptor and inhibition of
NMDA receptors. The dual mechanism of action has been responsible for the broad spectrum
anti-epileptic action (Rho et al., 1994). Meprobamate has also been known to have similar
action on GABAA and NMDA receptors. But while meprobamate both directly gate and
allosterically modulate GABAA receptors, felbamate has just direct gating action on GABAA
receptor (Rho et al., 1997). Clinically, while felbamate is mildly sedating, broad spectrum
antiepileptic agent, meprobamate has been shown to have a strong tranquilizing, sedating but
weak anti-epileptic effect (Rho et al., 1997). A detailed subunit dependent effect of felbamate
may explain the molecular basis for the differences in the clinical effects of the two drugs.

Most severe side effects of felbamate include aplastic anaemia and severe
hepatotoxicity. Others include nausea, vomiting, insomnia, anorexia, dizziness and headache.
Pharmacology and Metabolism of Meprobamate
Meprobamate is used either alone or in combination with other common over-thecounter drugs like, diphenhydramine, acetylsalicylic acid or codeine. Meprobamate
pharmacokinetics are unaffected by these commonly used combinations. However,
diphenhydramine metabolism is affected by meprobamate. Bioavailability is similar for oral or
rectal application (Gilbert et al., 1984).
After oral ingestion of a therapeutic dose, most of meprobamate is absorbed via GI
tract and peak plasma levels are reached within 1 hour to 3 hours. Less than 10 % of
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meprobamate was found in the feces (showing maximum absorption via GI tract). In studies
using carbon labelled meprobamate, meprobamate started appearing in the urine within 30
minutes and by 24 hours most of it was excreted from the body (Walkeinstein et al 1958).
Protein binding of meprobamate is negligibly small (14%–24%) and the volume of distribution
(Vd) was reported to be 0.70 L/kg and is not significantly altered in overdose (Verpooten et
al., 1982). 50% of amount of drug is unchanged meprobamate. Meprobamate is primarily
metabolized to inactive metabolites by the liver, primary metabolite being hydroxylmeprobamate and 10%–20% of the parent compound is excreted by the kidneys (Bismuth et
al., 1985). Elimination can be described by first-order pharmacokinetics and reported
elimination half-lives range between 6.4 hours and 16.6 hours in therapeutic dose and were
similar in overdose (Hollister et al., 1964; Maddock et al., 1967).
Meprobamate Side effects, Abuse and Withdrawal
Meprobamate was the first block-buster drug, selling billions of pills. It was supposed
to be free of toxic side effects, abuse and dependence potential. A common side effect of
meprobamate associated with regular use is allergic skin rashes, which appear in the form of
urticaria or erythema. They have been found in as high as 1-2% of patients taking the drug
(Hollister, 1957). Allergic rashes respond to drug withdrawal or concomitant use of antihistaminic medication. More severe form of skin reactions, like pustular skin lesions and
purpura, have also been reported (Friedman et al., 1956; Holoubek et al., 1957). These
promptly respond to discontinuation of the drug and corticosteroid therapy (Stroud, 1957).
Other common side effects associated with meprobamate use include nausea, dizziness,
drowsiness and fainting spells especially found when initial dose is more than 400 mg. An
alcoholic patient with long term use of high dose of meprobamate showed a grand mal epilepsy
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upon withdrawal (Pennington, 1957). A case of death with aplastic anemia has also been
reported with meprobamate use (Meyer et al., 1957).
Meprobamate was initially advertised as a non-addictive drug. Its good tranquilizing
effect along with relatively good safety profile prompted it to be sold without a prescription.
But many cases characteristic of a typical habit-forming drug were reported in the initial few
years of use of the drug. Addiction or a habit formation to a drug, has the following
characteristics: (1) an intense craving for the drug based on its euphoric effects, (2) tolerance
build up, requiring increasingly larger doses to produce the same effect, and (3) withdrawal
symptoms associated with sudden discontinuation of the drug (Lemere, 1956). An example
include a patient with a history of alcohol and barbiturate abuse and suffering excessive anxiety
at work, was prescribed meprobamate 400 mg 3 times a day. He had a good response, but had
to consume increasing doses of the drug to sustain the same response. Sometimes it was 50-70
tablets a day. An attempt at quitting led to anxiety and tremor and a grand mal seizure after 20
hours. Upon admission he was stuporous, confused and anxious and suffered another grand
mal seizure. He recovered after gradual weaning of the drug (Mohr et al., 1958). In another
studiy, patients did not show dependence (physical or psychic) or withdrawal even after
prolonged use of clinically effective dose (Boyd et al., 1958). So, other factors have been
associated with the development of meprobamate addiction and dependence, which include
amount of drug intake, previous history of drug abuse and personality of the patient. At the
peak of its use, meprobamate had been implicated in 7% of self-poisoning cases (Allen et al.,
1977).
Commonly known side effects of a meprobamate overdose include central nervous
system (CNS) depression, weakness, clonus and hyperactive reflexes, tachycardia,
hypotension and respiratory depression. Meprobamate also produces CNS-depressing
10

symptoms (Bramness et al., 2005) . Meprobamate intoxication is often serious and sometimes
fatal (5%), resulting from hemodynamic disturbance and circulatory collapse, secondary to
severe acute cardiac failure (Charron et al., 2005). In a case report, Lhoste et al., 1977,
suggested a predominant cardiogenic mechanism responsible for such hemodynamic failure.
The mechanism of cardiac toxicity is unknown. Patients with meprobamate poisoning were
shown to have a low cardiogenic index, ejection fraction, high right atrial pressure and
pulmonary capillary wedge pressure, showing a cardiogenic shock and thus a direct cardiac
effect (Lhoste et al., 1977; Charron et al., 2005). In a case of fatal meprobamate poisoning,
maximum meprobamate accumulation was found in heart, showing a possible direct cardio
toxic effect (Kintz et al., 1988). Also, ionotropic drugs have been useful in such cases, showing
presence of a cardiac depression (Lhoste et al., 1977; Taboulet et al., 1994). A related
compound, felbamate, is protective in cerebral ischemia and hypoxia (Wallis et al., 1992) via
a vasodilatory mechanism. Meprobamate, having a similar structure, may share some of this
vasodilatory effect. In the case report of Lhoste et al. 1977, a patient with severe meprobamate
poisoning had decreased peripheral resistance, unlikely in an isolated cardiogenic shock. Thus,
meprobamate-mediated hypotension is due to dual mechanism of direct cardiac depression and
peripheral vasodilatory effect.
An overdose of meprobamate also leads to an altered consciousness which corresponds
to its plasma concentrations. Below 5 mg/100 ml, patients have been found to be awake. A
non-serious coma occurs between 6-12 mg/100 ml and a deep coma is induced at
concentrations greater than 10 mg/100 ml (Maddock et al., 1967).
Recently, acute pancreatitis has also been reported as a possible effect of meprobamate
poisoning (Fathallah et al., 2011). Possible mechanism is stasis due to hypovolemia leading to
increased viscosity and thrombosis or a direct cellular toxicity (Underwood et al., 1993).
11

GABAA receptor
GABA is the primary inhibitory neurotransmitter in the CNS (Bormann, 2000) with
glycine, being the primary inhibitory neurotransmitter in the spinal cord (Betz et al., 1988;
Moss et al., 2001). Primary excitatory neurotransmitter in the CNS is the glutamate (Meldrum,
2000). GABA is synthesized from glutamate in a one step process by enzyme, L-glutamic acid
decarboxylase (GAD). Thus along with itself working as a neurotransmitter and a co-factor for
folic acid and hormone TSH (Thyrotropin releasing hormone), glutamate is used for the
synthesis of GABA (Erlander et al., 1991)(figure 1).
GABA receptors are of 3 types: GABAA, GABAB and GABAC. Considering similar
functional nature of GABAC receptor as GABAA, they have been nominated as a part of
GABAA receptor (Barnard et al., 1998). But there has been an accumulating evidence of a
distinct structure, function, pharmacology and genetics which makes the case of a separate
nomenclature (Bormann, 2000).
GABA interacts with GABAA receptors resulting in an opening of chloride channel
leading to depolarization and inhibitory post synaptic potential (IPSP). In some cases GABA
can be excitatory in nature. Example, in developing neurons, with high intracellular chloride
concentrations, a GABA interaction leads to an outward chloride flow and generation of an
excitatory post synaptic potential (EPSP) (Rivera et al., 1999). This phenomenon has a
profound effect on survival and differentiation during neuronal development (Ben-Ari et al.,
1997; Belhage et al., 1998).
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Figure 2: Features of a GABA Synapse.
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GABAA receptors are members of cys-loop ligand-gated ion channels. Cys-loop is a
characteristic loop formed by a disulfide bond between two cysteine (Cys) residues which are
13 highly conserved amino acids apart near the N-terminal extracellular domain of the alpha
subunit. Common members of this group are nicotinic acetylcholine receptors, Zn++ receptors,
type 3 serotonin (5HT3) receptors, glycine and GABAC receptors (Schofield et al., 1987;
Connolly et al., 2004). GABAA receptors are sensitive to bicuculline (Bormann, 1988;
Bormann, 2000) GABAA receptors are sites for many ligands like benzodiazepines,
barbiturates, alcohol, anesthetics and muscle relaxants like carisoprodol and meprobamate
(Akaike et al., 1985; Orser et al., 1994; Sigel et al., 1997; Kumar et al., 2015). GABAB
receptors are metabotropic G protein-coupled receptors sensitive to baclofen (Bormann, 1988;
Bowery, 1989; Marshall et al., 1999). They mediate their effect via signal transduction
pathways (Couve et al., 2000). Located on the presynaptic membrane, they inhibit the release
of inhibitory GABA in synaptic terminal. So overall having an excitatory effect. GABAB as a
therapeutic target has been less exploited (Bowery, 1989; Marshall et al., 1999). A different
type of receptor not sensitive to bicuculline or baclofen, previously known as GABAC receptors
(Johnston, 1996), are sensitive to GABA and the GABA analogue, aminocaproic acid. They
are also ligand-gated ion channel, composed of ρ-subunits, with the opening of chloride
channel on activation by GABA (Bormann et al., 1995; Johnston, 1996). However, they are
more sensitive and have a very weak desensitization. GABAC receptors are normally located
in the bipolar cells of retina (Shimada et al., 1992). As stated earlier, GABAC has unique
pharmacology compared to GABAA receptor. It is insensitive to bicuculline and baclofen
(Johnston, 1996). However ρ1-homomeric GABAC receptors were inhibited by picrotoxin like
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GABAA, while the ρ2-homomeric or ρ1ρ2 were not inhibited by picrotoxin (Cutting et al.,
1991; Enz et al., 1998; Feigenspan et al., 1998; Enz et al., 1999).

Structure of GABAA receptor and subunits classes and roles
GABAA receptor is a member of cys-loop ligand gated ion channels. Much has been
learned about the structure of of pentameric LGICs by solving of crystal structure of
acetylcholine binding protein (AchBP) (Brejc et al., 2001). Recently structure of GABAA
receptor itself has been solved (Miller et al., 2014). Cys loop ligand-gated ion channels are
pentameric in nature, i.e., each ion channel consists of 5 subunits (Toyoshima et al., 1990;
Nayeem et al., 1994). Each subunit consists of long extracellular N terminal domain, a short
extracellular c terminal domain, four trans-membrane (TM1-TM4) domains and connecting
loops. Connecting loops are short intracellular TM1-TM2 and a long intracellular TM3-TM4.
There is also a short extra-cellular TM2-TM3 connecting loop (Schofield et al., 1987; Unwin,
1993). Five of these subunits come together to form pentameric ion channel. The TM2 domain
of all the five subunit form the pore of the channel (Unwin, 1993; Xu et al., 1996). Extracellular
TM2-TM3 play an important part in channel gating, i.e., carrying information after binding of
ligand, leading to channel opening (Miyazawa et al., 2003; Thompson et al., 2010).
Above receptors were isolated using benzodiazepine affinity chromatography leading
to partial sequencing and cloning of two receptor genes. cDNAs for the two polypeptides
formed receptors with GABA activated current in Xenopus oocytes and these were designated
as α and β (Mohler et al., 1980; Schoch et al., 1985; Schofield et al., 1987; Sieghart, 1995).
These were used as probes to identify other subunits. Those with maximum homology
(70-80%) were assigned the same Greek letter and those with less homology (15-40%) were
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assigned different Greek letter. Thus so far the following GABAA receptor subunits have been
identified. α1-6, β1-3, γ1-3, δ, , ,  and ρ1-3 (Lynch et al., 1995; Lynch et al., 1997; Siegwart
et al., 2002). Some splice variants have also been identified. For example, the γ2 has a short
and a long form differing in the 8 amino acid insert in the intracellular (Whiting et al., 1990).
Similarly a short and a long form splice variant have also been identified for β2-subunit
(McKinley et al., 1995) .
So the above subunits assemble together to form hetero-pentameric, chloride
permeable channel. Out of the many possibilities of combinations, most common GABA A
receptor expressed in brain is 2 α, 2 β and one γ stoichiometry with the γ subunit, being able to
be replaced by δ, ,  or  subunit (Im et al., 1995; Chang et al., 1996; Tretter et al., 1997;
Baumann et al., 2001; Olsen et al., 2008). Out of all possible combinations, α1β2γ2 is most
abundant with approximately 60 % of the total GABAA receptor population. Distribution of
other combinations are α2β3γ2, 15-20%; α3βnγ2, 10-15%; α4βnγ2 or α4βnδ, 5%; α5β2γ2, <
5%; α6β2/3γ2, < 5% (Fritschy et al., 1995). Some GABAA receptor have two different αsubunits. In recombinant receptors, the α-subunit adjacent to the γ2-subunit determines the
sensitivity to the BZDs (Benke et al., 2004). Binding of GABA occurs at the interface of the α
and β-subunits (Baumann et al., 2003) while benzodiazepines bind at the interface of α and γsubunits (Sigel et al., 1997), leading to influx of chloride ions and generation of IPSP.
Functional roles of various subunits have been assessed using histidine to arginine
point mutations at a conserved residue. In α1, α2, α3 or α5 subunit, this mutation abolish the
binding of diazepam, whereas action of GABA is preserved (Rudolph et al., 1999; McKernan
et al., 2000; Crestani et al., 2002; van Rijnsoever et al., 2004). The positions are, α1H101R,
α2H101R, α3H126R, α5H105R.
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From the above mutation, it was assessed that α1 subunit-containing GABAA
receptors mediate sedative, partly anti-convulsant and anterograde amnestic action (Rudolph
et al., 1999); α2 subunit containing GABAA receptors mediate anxiolytic and myorelaxant
actions (large portion of it) (Low et al., 2000; Crestani et al., 2001); rest of myorelaxant action
is mediated by α3 and α5 subunit containing GABAA receptors (Low et al., 2000; Crestani et
al., 2001; Crestani et al., 2002); α5-containing GABAA receptor further mediate tolerance to
sedative action (van Rijnsoever et al., 2004); and addictive property α1-containing GABAA
receptors (Tan et al., 2010).
β-subunit also has important implications in health and disease. β3 subunit has been
associated with schizophrenia (Huang et al., 2014), genetic epilepsies (Macdonald et al., 2010),
autism (Delahanty et al., 2011), cleft palate (Inoue et al., 2008) as well as substance abuse
(Chen et al., 2014). Angelman syndrome, associated with mental disorders and developmental
delay and gait ataxia, is associated with the deletion of GABAA receptor β3 subunit (Williams
et al., 1995; DeLorey et al., 1998). In PTSD, a heterogenicty of β3 GABAA receptor is
associated with higher degree of anxiety insomnia and social dysfunction than a homozygocity
(Feusner et al., 2001).
Various modes of GABAA receptor activation
GABAA receptor synaptic communication transmits a pre-synaptic signal.
Depolarization following an action potential, lead to a calcium influx. Calcium causes synaptic
vesicles to fuse with the presynaptic membrane. Each vesicle release thousands of GABA
molecules, leading to a concentration in milli-molar range in the synaptic cleft. Some postsynaptic receptors exposed to GABA, have synchronous activation, leading to a phasic current
(Edwards et al., 1990; Mody et al., 1994; Nusser et al., 1997; Brickley et al., 1999). Synaptic
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GABAA receptors that mediate phasic currents are made up of mostly α1-3, β and γ subunits
(Rudolph et al., 2004). Phasic currents are characterized by fast activation, fast desensitization
and fast deactivation. One the other hand there is a tonic current mediated by highly sensitive
extrasynaptic-GABAA receptors, characterized by slow desensitization which can also open
spontaneously in absence of GABA (Brown et al., 2002; Tang et al., 2010; Wlodarczyk et al.,
2013). Extrasynaptic GABAA receptors are δ-containing (with mostly α1, α4 or α6) or γ subunit
with α5 (Fritschy et al., 1998; Brunig et al., 2002). δ subunit expressing receptors are
characterized by many remarkable properties. As stated earlier, they generate a tonic current
which are important component of CNS inhibition (Maguire et al., 2009; Bonin et al., 2011;
Sarkar et al., 2011). They regulate behaviors like memory and anxiety (Whissell et al., 2013;
Cushman et al., 2014; Lee et al., 2014; Paydar et al., 2014). They have a remarkable property
of different expression levels under different physiological and pathological conditions.
Neurosteroids mediate a stress-induced increase in expression of α4βδ GABAA receptors
(Maguire et al., 2005; Shen et al., 2005). Since these receptors constrain memory, their
upregulation in hippocampus may lead to stress-induced memory impairment. During
pregnancy, stimulation by steroid hormones cause upregulation of δ subunit (Smith et al., 2006;
Maguire et al., 2008). A partial or complete rebound following pregnancy may be responsible
for post-partum depression and abnormal maternal behavior which responds to
pharmacologically increasing delta activity. Expression of δ subunit and α4 subunit is reduced
in pre-frontal cortex (of suicide victims) in depression (Merali et al., 2004). δ-Expression is
reduced in schizophrenia (Hashimoto et al., 2008b; Hashimoto et al., 2008a; MaldonadoAviles et al., 2009) and an upregulation is observed in cases of stroke and traumatic brain
injury (Clarkson et al., 2010; Mtchedlishvili et al., 2010; Kharlamov et al., 2011). An
expression of δ subunit in various brain regions and its functional role is stated in figure 4. So
δ subunit expressing receptors have important physiological and pathological implications.
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Figure 3: Representation of GABAA receptors. A, GABAA receptor subunit consists of
long N-terminal domain, short C-terminal domain, 4 transmembrane (TM1-TM4) domain and
long intracellular TM3-TM4 loop. B, 5 of the subunits assemble to form a pentameric cys loop
ligand gated ion channel with GABA binding site between α and β-subunit and benzodiazepine
binding site between α and γ-subunit. Note, in recombinant receptors, the α-subunit adjacent
to the γ-subunit determine the sensitivity to the benzodiazepines. C, synaptic and extrasynaptic GABAA receptors composed of α1-3, β , γ and α4-α6, β, δ respectively. α 5 βγ also
form extrasynaptic GABAA receptors.
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Figure 4: Delta GABAA expression and function in CNS. Red show a high expression level
while orange a medium and yellow low level of expression. Probable functions are stated in
boxes.
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Pharmacology of GABAA receptors
Ligands have various modes of action on GABAA receptors. These include direct
activation, allosteric modulation, inverse agonism and antagonism. Direct activation involves
activation of receptor in the absence of GABA via the GABA site or a different site. Common
ligands capable of direct activation are barbiturates, common tranqilizers and muscle relaxants
like carisoprodol (Kumar et al., 2015) and meprobamate (Kumar et al. 2015, accepted pending
revision). Ligands capable of direct activation at all the α subunits are commonly associated
with fatal complications (Rho et al., 1997; Fass, 2010). Allosteric modulation is effect of a
ligand on GABA mediated current via a different binding site. Common ligands capable of
allosteric modulation are benzodiazepines and barbiturates (Hunkeler et al., 1981).
Barbiturates, carisoprodol and meprobamate are capable of both direct action and allosteric
modulation whereas benzodiazepines do not have a direct gating effect at GABAA receptors.
An inverse agonist is a ligand having an effect opposite to that of an agonist (Braestrup et al.,
1982; Bonetti et al., 1988). Antagonists do not have effects on their own on the receptor but
block current by both the agonists and the inverse agonists. Common antagonists at GABAA
receptors are picrotoxin and bicuculline (Bormann, 2000). Common antagonist at the
benzodiazepine site on GABAA receptor is flumazenil (Hunkeler et al., 1981).
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Aims of the study
So, the main aim of this study is to understand a detailed mechanism of action of
meprobamate on the various subunits of GABAA receptors. To understand whether
meprobamate has a direct gating, allosteric modulatory or inhibitory effects on GABAA
receptors. Meprobamate, though earlier was widely prescribed and later controlled, is the major
metabolite of currently widely prescribed muscle relaxant, carisoprodol. Carisoprodol has
direct gating, allosteric modulatory and inhibitory actions on GABA A receptor subunits. We
wanted to test the hypothesis that meprobamate also has similar actions on GABAA receptors
and the difference attributed to the difference in the structure of the two ligands. Carisoprodol
has an isopropyl group that is absent in meprobamate.
Mechanism of action of meprobamate, known so far, is its action on GABAA receptor
in a barbiturate like manner. So, we also wanted to test how similar and different is the action
of meprobamate to barbiturates, represented in our studies by pentobarbital.
We further set out to explore the specific amino acids and domains responsible for the
various modes of action of meprobamate on GABAA receptors. To summarize, the aims of
study are as follows:
AIM 1: To determine the degree to which the lack of the isopropyl group may alter
potency, efficacy and subunit preferring effect of meprobamate compared to CSP
AIM 2: To determine the extent to which actions overlap between meprobamate and
barbiturate pentobarb
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Abstract
Meprobamate is a schedule IV anxiolytic and the primary metabolite of the muscle relaxant
carisoprodol. Meprobamate modulates GABAA (-aminobutyric acid type A) receptors, and has
barbiturate-like activity. To gain insight into its actions, we have conducted a series of studies
using recombinant GABAA receptors. In xz GABAA receptors (where x = 1-6 and z = 1-3),
the ability to enhance GABA-mediated current was evident for all  subunit isoforms, with the
largest effect observed in 5-expressing receptors. Direct gating was present with all  subunits,
although attenuated in α3-expressing receptors. Allosteric and direct effects were comparable in
112 and 122 receptors, whereas allosteric effects were enhanced in 12 compared to
122 receptors. In “extrasynaptic” (α1β3δ and α4β3δ) receptors, meprobamate enhanced EC20
and saturating GABA currents, and directly activated these receptors. The barbiturate antagonist
bemegride attenuated direct effects of meprobamate.

Whereas pentobarbital directly gated

homomeric β3 receptors, meprobamate did not, and instead blocked the spontaneously open current
present in these receptors. In wild type homomeric ρ1 receptors, pentobarbital and meprobamate
were ineffective in direct gating; a mutation known to confer sensitivity to pentobarbital did not
confer sensitivity to meprobamate. Our results provide insight into the actions of meprobamate
and parent therapeutic agents such as carisoprodol. Whereas, in general, actions of meprobamate
were comparable to those of carisoprodol, differential effects of meprobamate at some receptor
subtypes suggest potential advantages of meprobamate may be exploited. A re-assessment of
previously synthesized meprobamate-related carbamate molecules for myorelaxant and other
therapeutic indications is warranted.

Key words: GABAA receptor; meprobamate; carisoprodol; muscle relaxant; drug abuse
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1. Introduction
Meprobamate, a propanediol carbamate, was the first drug to be used as an anxiolytic agent,
and was also prescribed as an anticonvulsant and sedative/hypnotic (Hendley et al., 1954). By the
late 1950s, meprobamate was the most widely prescribed drug in the United States and in many
other countries. It retained this position until diazepam the benzodiazepine diazepam was
introduced into clinical use in late 1960 (Berger, 1964; Greenblatt et al., 1974). Within two years
of introduction of meprobamate, cases of its abuse and withdrawal after long term use were reported
(Ewing et al., 1957), and it was relatively soon thereafter listed as a controlled substance.
While meprobamate itself is no longer widely used, drugs metabolized to meprobamate are
widely available, and misuse of these drugs is associated with serious side effects. One such drug
is the centrally acting skeletal muscle relaxant carisoprodol, which remains highly prescribed for
low back pain (Toth et al., 2004; Sullivan, 2015). Use of carisoprodol is associated with abuse and
dependence, and related dangers such as psychomotor impairment (Elder, 1991; Rust et al., 1993;
Zacny et al., 2011, 2012). Dependence and severe withdrawal may lead to seizures and death
(Adams et al., 1975; Elder, 1991; Littrell et al., 1993; Rust et al., 1993; Reeves et al., 2003; Zacny
et al., 2011; Zacny et al., 2012). Although carisoprodol has its own independent effects (Gonzalez
et al., 2009b), many of its therapeutic and abuse-dependent effects are likely due to its metabolite
meprobamate, which differs from carisoprodol by the absence of an isopropyl group (Fig. 1).
Indeed, the half-life of meprobamate far exceeds that of carisoprodol ( t ½ for carisoprodol of 1-2
hours (Olsen et al., 1994) and t ½ for meprobamate between 6.4 hours and 16.6 hours (Hollister et
al., 1964; Maddock et al., 1967).
Meprobamate has been shown to have barbiturate-like activity at neuronal GABAA
receptors (Rho et al., 1997), the predominant inhibitory neurotransmitter receptor in the central
nervous system and the target of many therapeutics. Carisoprodol has similarly been suggested to
have barbiturate-like actions (Gonzalez et al., 2009a). A detailed understanding of meprobamate’s
interaction with GABAA receptors is lacking, however. For instance, the extent to which its
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interaction with GABAA receptors may be subunit-dependent is unknown. As the extensive array
of GABAA receptor configurations that exist throughout the CNS contribute to specific
physiological and pharmacological responses of GABA and modulatory agents (Olsen et al., 2008),
an understanding of meprobamate’s subunit-dependent actions could prove enlightening regarding
therapeutic and adverse effects of both it and parent therapeutics that are metabolized to
meprobamate, such as carisoprodol. We have thus assessed the potential subunit-dependent
interaction of meprobamate at these receptors and have further explored potential commonality and
differences of action with barbiturates.
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2. Materials and Methods

2.1 Cell Culture and Transfection
Human embryonic kidney 293 (HEK293) cells, stably or transiently expressing varying
GABAA receptor subunits, were used in the present study. For transient expression, cells were
transfected with human GABAA α1-α6; human β1-2; and human 2s (short isoform) cDNA in a
1:1:5 ratio (2 g total cDNA) using PolyJetTM in vitro transfection reagent (SignaGen Laboratories,
Jamesville, MD). The 2s subunit will be referred to as 2 from here forward. For studies assessing
meprobamate effects in a model of extrasynaptic receptors (rat 13 and 43 subunits), a total
of 3 g of cDNA in a transfection ratio of 2:1:0.25 for α:β:δ plasmids was used (Wagoner et al.,
2010). For studies on wild type 3 homomeric receptors, wild type 1 subunits, and barbituratesensitive 1 (W328M) subunits (generated previously in our lab, Gonzalez et al, 2009b), 2 g of
cDNA was transfected. The rat GABAA α4 subunit cDNA was purchased from Genescript
(Piscataway, New Jersey). Human GABAA α1 subunit cDNA was generously provided by Neil
Harrison (Columbia University Medical Center, New York). The wild-type human GABA 1
subunit was generously provided by David Weiss (University of Texas Health Science Center at
San Antonio). HEK293 cells stably expressing human 222 receptors were also used. A
complete description of the preparation and maintenance of these stable cell lines has been
published previously (Hawkinson et al., 1996). Cells were plated on glass coverslips coated with
poly-L-lysine in 35-mm culture dishes, and maintained at 37C in a humidified incubator with an
atmosphere of 5% CO2. In all cases, cells were used for recording 24-72 hr after transfection.

2.2 Electrophysiology
Whole-cell patch clamp electrophysiology was used to assess GABA-, meprobamate–, or
pentobarbital-activated Cl- currents. All electrophysiology experiments were conducted at room
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temperature (22 - 25 C) with the membrane potential clamped at -60 mV. Patch pipettes of
borosilicate glass (1B150F; World Precision Instruments, Inc., Sarasota, FL) were pulled
(Flaming/Brown, P-87/PC; Sutter Instrument Company, Novato, CA) to a tip resistance of 4–6MΩ.
Patch pipettes were filled with a solution consisting of 140 mM CsCl, 10 mM EGTA-Na+, 10 mM
HEPES-Na+, and 4 mM Mg2+-ATP, pH 7.2. Coverslips containing cultured cells were placed in the
recording chamber on the stage of an inverted light microscope and superfused continuously with
an external solution consisting of 125 mM NaCl, 20 mM HEPES, 3 mM CaCl2, 5.5 mM KCl, 0.8
mM MgCl2, and 10 mM glucose, pH 7.3. Agonist-induced Cl- currents were obtained with an
Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) equipped with a CV-203BU
headstage. Currents were low-pass filtered at 5 kHz, monitored simultaneously on an oscilloscope
and a chart recorder (Gould TA240; Gould Instrument Systems Inc., Cleveland, OH), and stored
on a computer using an on-line data acquisition system (pCLAMP 6.0; Axon Instruments) for
subsequent off-line analysis.

2.3 Chemicals and solutions
Meprobamate,

carisoprodol,

pentobarbital,

diazepam,

THIP

(4,5,6,7-

tetrahydroisoxazolo(5,4-c)pyridin-3-ol), salts and buffers were purchased from Sigma Aldrich (St.
Louis, MO). GABA was obtained from Acros Organics (New Jersey, US). Bemegride was obtained
from Pfaltz & Bauer, Inc. (Waterbury, CT). Stock solutions of meprobamate, pentobarbital and
carisoprodol were made using dimethylsulfoxide (DMSO). Drugs were diluted in normal saline,
so that the final DMSO concentration (vol/vol) of the test solutions was ≤0.3%. GABA, diazepam
and bemegride stock solutions were prepared using de-ionized H2O. All stock solutions were stored
at -20 C. On experimental days, drug-containing solutions were prepared from stock by serial
dilution into external solution.
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2.4 Experimental Protocol
GABA (with or without modulatory ligand), meprobamate, carisoprodol or pentobarbital
were prepared in external solution on the day of use and applied via a 16-barrel rapid perfusion
system in which all barrels (200 µm outer diameter quartz tubes; ALA Scientific, Folsom, CA)
emptied via a common tip positioned adjacent to the cell under study. Flow through each barrel
was pressure fed and regulated by solenoid or pinch valves operated by a programmable
microprocessor-based controller. Only one valve was open at a time, and the buffer solution was
applied continuously between drug applications via gravity or positive pressure. As per the
manufacturer specifications, solution flow rate as configured in the present studies is approximately
3 l/second, and exchange rate is approximately 5 msec. For some experiments, ligands were
applied via gravity flow using a Y-tube placed adjacent to the cell.
The modulatory effects of meprobamate on GABA-gated currents were assessed using an
EC20 gating concentration of GABA as the control. This gating concentration was selected to ensure
there was a sufficient range to observe the full allosteric potential of meprobamate. To ensure the
gating concentration was approximately an EC20, control responses were compared to the maximal
GABA-gated current for each individual cell. On a cell by cell basis, control GABA currents were
deemed acceptable for assessment of allosteric modulatory effects of meprobamate if they were
within a 15-25 % range of maximal current for that particular cell. Control responses were
established by observing two consecutive agonist-activated currents that varied in amplitude by no
more than ± 10%. In our analyses of the modulatory effects of meprobamate, peak current
amplitude was defined as the maximum current elicited by meprobamate. For studies investigating
meprobamate-mediated currents, meprobamate was dissolved in external solution and applied in
the manner described above. In all studies assessing direct gating effects of meprobamate, the
magnitude of the response was expressed relative to the maximal effect of GABA (designated
100%). In studies on β3 homomeric receptors, the magnitude of meprobamate-mediated block of
spontaneously open channels was measured relative to the maximal blocking effect of picrotoxin
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(designated 100%). For configurations, GABA-gated control currents were recorded in the
presence of diazepam to confirm incorporation of the 2 subunit. Presence of the δ subunit in α1β3δ
and α4β3δ receptors was confirmed by loss of inhibition to 1 µM Zn2+.

2.5 Data Analysis
To ensure equipotent concentrations were used for gating, GABA concentration-response
data were collected for all synaptic and extrasynaptic GABAA receptors tested, (Table 1). From
these data, EC20 and saturating GABA concentrations were calculated for each configuration and
used in subsequent investigations of the allosteric and direct effects of meprobamate, respectively.
For studies assessing allosteric actions of meprobamate, a correction was applied to subtract
underlying direct gating effects, which were present at higher meprobamate concentrations. All
data are presented as mean ± S.E.M. For experiments in which three or more datasets were
statistically analyzed, one-way analysis of variance was conducted, followed by a Tukey-Kramer
post hoc test as indicated. For those experiments in which two datasets were analyzed, Student’s
t-tests (paired or unpaired) were conducted. In all cases, statistical significance was designated at
a p value of 0.05 or less.
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3. Results

3.1 α subunit isoform influence on direct and allosteric actions of meprobamate
Direct effects of meprobamate were assessed in x22 GABAA receptors, where x = α
subunit 1-6. We initiated direct gating studies using concentrations of meprobamate as low as 100
M; as direct gating effects were not generally observed below 1 mM, we report here direct gating
effects of 1, 3 and 10 mM meprobamate. Meprobamate directly gated each of the configurations
tested at high concentrations, evoking inward currents in the absence of GABA (Fig. 2). The
relatively low apparent affinity of meprobamate combined with limits on its solubility precluded
definitive calculation of maximal meprobamate-gated current. At 10 mM, meprobamate-gated
current was of similar magnitude in α1-, α2-, α4-, α5- and α6β2γ2s GABAA receptors (20-36% of
maximal GABA current), and significantly less (7%) in α3-expressing receptors (Fig. 2).
We also assessed  subunit isoform effects on allosteric modulatory actions of
meprobamate. Meprobamate positively modulated the effects of GABA EC20 concentration in all
configurations tested (Fig. 3). 3 mM meprobamate on average roughly doubled the amplitude of
the GABA EC20 current for most subunit isoforms. We observed a somewhat enhanced effect in
receptors expressing the 5 subunit, as 3 mM meprobamate elicited a potentiating effect of more
than 3-fold (Fig. 3).

3.2  subunit isoform influence on direct and allosteric actions of meprobamate
To assess whether the  subunit isoform affected the actions of meprobamate, we assessed
both direct and allosteric effects of it in α1β2γ2 and α1β1γ2 receptors. We observed no significant
difference in the magnitude of current elicited by meprobamate alone in these receptors, as 10 mM
meprobamate elicited currents roughly 1/3 the amplitude of peak GABA current in both α1β2γ2
and α1β1γ2 receptors (Fig. 2C).
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With regard to  subunit effects on allosteric actions of meprobamate, we found receptors
expressing either β1 or β2 subunits (in combination with α1 and 2) showed similar allosteric
modulation by meprobamate. In both receptors, 3 mM meprobamate effectively doubled the
amplitude of GABA-gated current (Fig. 3C).

3.3  subunit isoform influence on direct and allosteric actions of meprobamate
Presence of a  subunit is critical for the allosteric actions of benzodiazepines (Pritchett et
al., 1989), but not for direct or allosteric effects of other ligands such as barbiturates (Horne et al.,
1993) or neurosteroids (Hosie et al., 2006). To assess the extent to which the  subunit impacts
actions of meprobamate, we tested effects of it in receptors lacking the 2 subunit. In comparison
to α1β2γ2 receptor, direct gating in α1β2 receptor was generally comparable. There was a
statistically smaller direct gating response at 1 mM meprobamate in α1β2 receptor compared to
α1β2γ2 receptor, but this difference was modest and not present at other concentrations tested (Fig.
2D).
The 2 subunit had a more prominent effect on allosteric modulation by meprobamate. Its
presence significantly attenuated the ability of meprobamate to allosterically an EC20 concentration
of GABA at all concentrations of MEP above 100 M. At 1 and 3 mM MEP, the magnitude of
enhancement in α1β2 receptors was more than twice that observed in α1β2γ2 receptors (Fig 3D).

3.4 Effects of meprobamate on -subunit containing “extrasynaptic” receptors
GABA and ligands that regulate its receptors may act at synaptic or extrasynaptic sites. To
assess the influence of meprobamate extrasynaptically, we studied its effect in recombinant α4β3
and α1β3receptors, models of extrasynaptic GABAA receptors. As reported by others (Brown et
al., 2002), sensitivity of α4β3 receptors to GABA was high, with an EC50 of 0.04 ± 0.02 µM. As
shown in Figure 4, meprobamate directly gated α4β3 receptors with an efficacy comparable to
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that of GABA itself. This direct gating effect was concentration-dependent, and saturated at 3 mM
meprobamate. We found very similar effects for the ability of meprobamate to directly gate
α1β3receptors. Sensitivity to the direct gating effects in extrasynaptic receptors was comparable
to that observed in synaptic receptors. Current gated by meprobamate rapidly decayed following
activation, and we noted a prominent rebound effect following termination of ligand application
(Fig 4A, arrow). GABA is not a full agonist in expressing receptors (Brown et al., 2002); we
observed the same effect, as the agonist THIP elicited a current 151 ± 12% of that elicited by
saturating GABA.
We also assessed the extent to which meprobamate might allosterically potentiate
extrasynaptic GABAA receptors. As illustrated in Fig. 5, meprobamate enhanced GABA-gated
(EC20) current, with a threshold effect at 100 M, and a maximal effect observed at 1 mM. The
sensitivity and magnitude of the potentiating effect is comparable to that observed in synaptic
receptors.
Pentobarbital and carisoprodol, the parent molecule to meprobamate, have been reported
to enhance maximal GABA-gated current in δ-subunit containing receptor (Feng et al., 2004;
Kumar et al., 2015). We thus assessed for this capability with meprobamate. Co-application of 1
mM meprobamate with 1 mM GABA (EC95+) to α4β3 receptors resulted in a current 183 ± 17%
of that seen with maximal GABA alone. As anticipated, 100 µM pentobarbital, which was used
as a positive control, showed enhancement of maximal GABA-gated current (to 223 ± 38% of
maximal GABA, Fig. 6B). No enhancement was observed in α1β3γ or α1β3 subunit containing
receptors with meprobamate or pentobarbital (Fig. 6B).

3.5 Further assessment of the barbiturate-like effects of meprobamate
Based on a mechanistic assessment of its effects in GABAA receptors recorded from
cultured rat hippocampal neurons, others have concluded meprobamate has “barbiturate-like”
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activity (Rho et al., 1997). Our results are broadly consistent with that suggestion. We thus
conducted additional studies to test further commonality of action between meprobamate and
pentobarbital.
Bemegride is known to antagonize pentobarbital stimulus effect in animal models
(Schechter, 1984) and phenobarbital direct gating effects in mouse spinal neurons (Mistry et al.,
1990). We thus assessed the influence of bemegride on the direct gating effects of meprobamate.
As shown in Figure 7, meprobamate-mediated direct gating current was significantly and reversibly
attenuated by bemegride. The ability of bemegride to antagonize meprobamate-activate current
was greater when tested against a lower concentration of meprobamate, demonstrating a
concentration-dependent effect.
1 homomeric GABA receptors are anion-selective cys loop ligand-gated channels, with
a pharmacology distinct from that of heteromeric GABAA receptors (Amin et al., 1994). They are
found in very high concentration in retina and other visual areas (Enz et al., 1995; Boue-Grabot et
al., 1998). Barbiturates cannot directly activate wild type 1 homomeric GABA receptors, but can
when tryptophan at position 328 is mutated to methionine (W328M) (Amin, 1999). We assessed
whether meprobamate can gate wild type or W328M 1 homomeric GABA receptors. In wild type
homomeric ρ1 receptors, both pentobarbital and meprobamate were ineffective in direct gating
(Fig. 7A, 7B). As originally reported (Amin, 1999), we observed that the W328M mutation in the
1 subunit conferred sensitivity to direct gating effects of pentobarbital. In contrast, the W328M
mutation did not confer on meprobamate the ability to directly gate the channel (Fig. 7A, 7B).
Homomeric β3 receptors do not appear to form natively, but they can form a functional
receptor in vitro, and thus are a useful tool for studying drug action (Davies et al., 1997; Chen et
al., 2012). Homomeric β3 receptors are spontaneously open, and they can be directly activated by
barbiturates (Davies et al., 1997). We evaluated whether meprobamate had direct gating effects in
these receptors. Meprobamate, in contrast to pentobarbital, could not directly gate homomeric β3
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receptors. Instead, meprobamate, blocked the spontaneously open current present in homomeric β3
receptors (Fig. 7A, 7B). This effect was concentration-dependent, and approached the efficacy of
the GABA receptor antagonist picrotoxin in blocking the spontaneously open channel (Fig. 7B).
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4. Discussion
This is the first study to assess subunit-dependent effects of meprobamate at its major
target, GABAA receptors.

Drugs metabolized to meprobamate, such as carisoprodol, have

remained widely utilized. Carisoprodol was actually synthesized as an alternative to meprobamate,
and early studies suggested it had a profile that was preferable to meprobamate (Berger et al., 1960).
Early metabolism studies in dogs indicated the primary metabolite of carisoprodol was hydroxylcarisoprodol (Douglas et al., 1962). Toxicology studies some years later demonstrated that in
humans, carisoprodol was in fact metabolized primarily to meprobamate, which has a half-life that
is several-fold longer than that of carisoprodol (Bramness et al., 2004; Olsen et al., 1994). Whereas
the recent scheduling of carisoprodol will likely result in a reduction in its use (Bramness et al.,
2012), it remains a key therapeutic for treatment of acute low back pain (Witenko et al., 2014).
Even with its recent scheduling, a quick internet search reveals a number of pharmacies noting the
ready availability of carisoprodol without a prescription. Thus the potential for continuing abuse
of carisoprodol remains. Considering a significant proportion of its effect are likely attributable to
its metabolite meprobamate, the focus of the present study was thus to gain greater insight into
meprobamate modulation of its major therapeutic target, the GABAA receptor.
Our assessment of meprobamate’s ability to directly gate and allosterically modulate the
GABAA receptor is comparable to that reported in neurons (Rho et al., 1997), in that both effects
are of relatively low potency. Rho et al. (1997) further categorized its actions as “barbiturate-like”,
and carisoprodol also displays barbiturate-like effects both in vivo and in vitro (Gonzalez et al.,
2009b). We conducted a number of experiments to better understand the extent to which effects of
meprobamate mimic those of the barbiturate pentobarbital.

The results demonstrate some

commonality of effect between the two ligands, but in general do not support a common site of
action for meprobamate and barbiturates. The barbiturate antagonist bemegride reversibly and
significantly inhibited meprobamate-mediated direct gating current in a concentration-dependent
manner, consistent with a competitive nature of inhibition. However, in homomeric ρ1 receptors,
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a mutation (W328M) that conferred sensitivity to pentobarbital (Amin, 1999) did not confer
sensitivity to meprobamate. In addition, whereas pentobarbital could directly gate homomeric β3
receptors, this effect was not observed with meprobamate. Thus, whereas a number of in vivo and
in vitro actions of meprobamate are in fact similar to those observed with pentobarbital, the
comparison cannot be extended to indicate a common binding domain for these ligands. In this
regard, meprobamate is comparable to carisoprodol (Gonzalez et al., 2009b). Recent photoaffinity
labeling studies have provided considerable evidence that barbiturates bind to inter-subunit
interfaces in GABAA (Chiara et al., 2013) and nicotinic (Hamouda et al., 2014) receptors. With
regard to GABAA receptors, a photoreactive barbiturate binds to a number of residues at both the
 and  interfaces in the transmembrane domain (Chiara et al., 2013). Our current results
suggest it unlikely that meprobamate would interact with those residues.
It has become increasingly clear in recent years that many therapeutic and adverse actions
of GABAergic drugs associate predominantly with particular subunits of the GABA A receptor
(Low et al., 2000; Crestani et al., 2001; Crestani et al., 2002; van Rijnsoever et al., 2004; Licata et
al., 2008; Tan et al., 2010; Rudolph et al., 2014). Of particular relevance to the current study is the
fact that 2- and 3 expressing receptors are involved in both anxiolytic (Low et al., 2000; Crestani
et al., 2001; Licata et al., 2008) and muscle-relaxing (Crestani et al., 2001; Griebel et al., 2003)
effects of GABAergic ligands, while abuse potential associates with the 1 subunit (Licata et al.,
2008; Tan et al., 2010). Our recent report (Kumar et al., 2015) shed some light on the subunitdependent effects of carisoprodol itself and how they may relate to its therapeutic and advserse
effects. To fully understand actions of carisoprodol, it is necessary to also understand potential
subunit-dependent effects of the primary and comparatively long-lived metabolite, meprobamate.
At the maximal concentration assessed, meprobamate-gated current was of similar magnitude in
α1-, α2-, α4-, α5- and α6β2γ2s GABAARs, and significantly less in α3-expressing receptors. The
parent drug carisoprodol has a similar profile, with roughly three-fold higher potency (Kumar et
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al., 2015). With regard to allosteric modulation, carisoprodol displayed considerably greater
efficacy in α1-expressing receptors (Kumar et al., 2015), whereas meprobamate displayed generally
similar effects regardless of  subunit, with some enhanced efficacy in 5-expressing receptors.
The lack of effect of  subunit isoform on direct gating or allosteric effects of meprobamate
contrasts with carisoprodol, in which direct gating was most efficacious in 1-expressing receptors,
and allosteric modulation was greatest in 2-expressing receptors (Kumar et al., 2015). In addition,
whereas the γ subunit did not have an effect on direct gating or allosteric modulation of carisoprodol
(Kumar et al., 2015), its presence quite markedly attenuated the modulatory capacity of
meprobamate. This effect may not be therapeutically significant as few native receptors express
only  and  subunits, but it may prove useful in identifying critical domains for effects of
meprobamate.
Ligands that influence the actions of GABA may also act at extrasynaptic GABA A
receptors, which include α4β3δ and α1β3δ subtypes; these receptors have been implicated in
diseases such as schizophrenia, depression and epilepsy (Brickley et al., 2012). Meprobamate
directly gated these receptors with an efficacy comparable to that of GABA, which is a partial
agonist in these receptors (Bianchi et al., 2003). We also observed that GABA’s efficacy was about
2/3 that of the full agonist THIP in δ subunit-expressing receptors. Barbiturates (Feng et al., 2004),
neurosteroids (Wohlfarth et al., 2002) and the parent drug carisoprodol (Kumar et al., 2015) all
have the ability to enhance the actions of a saturating concentration of GABA in extrasynaptic
receptors. We observed a similar effect of meprobamate in the present investigation. Whereas a
portion of the peak GABA current enhancement could be attributable to some direct action of
meprobamate, the majority of the enhancement may relate to shifting of GABA from a low efficacy
to high efficacy ligand (Bianchi et al., 2003).
In considering where on the receptor meprobamate acts, key questions include: 1) is the
site(s) where meprobamate acts the same as that for carisoprodol?; and 2) does meprobamate acts
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at distinct sites for gating and allosteric effects? When initiating these studies, we hypothesized that
the two ligands act at the same site for both effects. As noted, experimental evidence has shown
that both carisoprodol and meprobamate allosterically modulate, directly gate and inhibit the
GABAA receptor. Both ligands also display similar actions at -expressing receptors. Specifically
with regard to question 1 above, we consider here both direct and allosteric effects. Results for
direct gating studies demonstrate the subunit-dependent profile for the two ligands are quite similar,
and the main difference between the two ligands is potency. These data are consistent with a single
overlapping site of action. The isopropyl group of carisoprodol may enhance hydrophobic
interactions that result in its enhanced potency. In considering allosteric modulatory effects of the
two ligands, the subunit-dependent profile showed significantly more variability than that observed
for direct gating effects. The influence of  and  subunits was different for meprobamate
compared to carisoprodol.

Although a definitive conclusion is not warranted, the data are

consistent with only modestly overlapping or possibly distinct sites for allosteric effects of
meprobamate, compared to carisoprodol. Further studies are required to more definitively address
this issue.
In considering whether the direct and allosteric effects of meprobamate are mediated via
one or two sites, the possibility of two sites is likely. With regard to carisoprodol, separate sites
for direct gating and allosteric modulatory effects have been proposed (Kumar and Dillon, 2015).
As with carisoprodol, the subunit-dependent profiles for direct and allosteric effects of
meprobamate are distinct.

Additional evidence suggestive of distinct sites comes from recent

mutagenesis studies. We have reported in abstract form (Kumar et al., 2013) the fact that amino
acid mutations in transmembrane domain IV of the  subunit impact direct gating of carisoprodol,
but have no significant effect on its allosteric actions. Unpublished results of effects of these
mutations on the actions of meprobamate suggest a similar effect. Whether the amino acid residues
in question form part of the binding site for these ligands or are critical for transduction is not
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known. Nevertheless, the fact that the mutations had effects only on direct gating is consistent with
the conclusion that distinct sites exist for direct and allosteric modulatory effects for both
meprobamate and carisoprodol.
Our results provide additional insight regarding the therapeutic and abuse-facilitating
effects of carisoprodol. Both carisoprodol and meprobamate display direct gating and allosteric
modulatory effects on GABAA receptors across the spectrum of expressing receptors, which
supports physical dependence and abuse potential (Licata et al., 2008). Both ligands effectively
modulate α2-, α3- and α5-expressing receptors, which provides an effective muscle relaxant profile
(Crestani et al., 2001; Griebel et al., 2003.

Drawing further from an understanding of

benzodiazepines, the considerably higher efficacy (and potency) of carisoprodol for allosteric
enhancement of α1-expressing receptors would seem to be a key contributor for its abuse and
addictive potential (Licata and Rowlett, 2008; Tan et al., 2010). In addition, in a study of impaired
and unimpaired drivers, blood concentration of carisoprodol, but not meprobamate, correlated with
driver impairment (Bramness et al., 2004). The authors concluded that carisoprodol itself has
impairing effects. As sedative effects are strongly associated with activity at 1-expressing
receptors, our finding that meprobamate has considerably reduced effects at these receptors,
compared to carisoprodol, provides a molecular basis in support of the conclusion of Bramness et
al. (2004). Meprobamate itself has important limitations as a therapeutic; hence its classification
as a scheduled drug decades ago. However, as meprobamate strongly modulates α5-expressing
receptors (consistent with muscle relaxant effects), and has comparatively inefficient ability to
modulate α1-expressing receptors (associated with dependence and abuse potential), a reevaluation of meprobamate for possible modification is warranted.
During the time period both meprobamate and carisoprodol were being widely prescribed,
an extensive series of derivatives of them was generated (Ludwig et al., 1969). Many of these
displayed enhanced potency for muscle relaxation (as measured via paralyzing effects that leads to
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loss of righting reflex) compared to both carisoprodol and meprobamate, as well as an enhanced
safety margin. It appears none of these molecules made it to market. Whether they failed for safety
or other reasons, or whether the decision to abandon this series of compounds was made in light of
the subsequent scheduling of meprobamate is not known. Considering the availability of improved
assays and our current understanding of molecular pharmacology associated with therapeutic
effects, it might prove worthwhile to re-assess a number of these meprobamate-related carbamate
molecules for myorelaxant and other indications.
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Table 1. GABA sensitivity of the GABAA receptor subunit configurations studied. EC50
values for each receptor are expressed as mean ± S.E.M.
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Receptor
Configuration

EC50 (µM)

n

α1β2

16.4 ± 2.39

5

α1β2γ2

28.6 ± 2.75

8

α2β2γ2

32.8 ± 1.81

5

α3β2γ2

34.8 ± 2.09

8

α4β2γ2

5.9 ± 0.16

5

α5β2γ2

0.8 ± 0.23

4

α6β2γ2

1.7 ± 0.24

4

α1β1γ2

15.7 ± 0.15

7

α4β3δ

0.04 ± 0.02

4
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Figure 1. Structure of meprobamate and a prominent parent molecule, carisoprodol.
The molecules differ by an isopropyl present on one of carisoprodol’s carbamyl nitrogens; the
isopropyl is removed by CYP2C19 to form meprobamate.
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Figure 2. Assessment of subunit-dependent effects of meprobamate on direct activation
of GABAA receptors. A, Representative traces demonstrating direct activation by
meprobamate in α1β2γ2, α3β2γ2, α1β2 and α1β1γ2 receptors. B, C and D, summary data of
meprobamate mediated direct-gating effects associated with varying  and  subunits,
respectively. Direct activation capability was diminished in α3β2γ2 compared to the other
configurations, whereas varying the  subunit or deleting the 2 subunit had negligible effects.
Each data point represents the mean ± S.E.M. of a minimum of 4 cells. *, p < 0.05; **, p <
0.01.
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Figure 3. Assessment of subunit-dependent effects of allosteric modulatory effects of
meprobamate on GABAA receptors. A, Representative traces demonstrating direct allosteric
potentiation by meprobamate of GABA-gated (EC20) currents in α1β2γ2, α3β2γ2, α1β2 and
α1β1γ2 receptors. B, C and D, summary data of allosteric effects of meprobamate associated
with varying  and  subunits, respectively. Allosteric potentiation was present in all 
receptors, but greatest in those expressing the 5 subunit; absence of the  subunit also resulted
in enhanced potentiation. Note for this and other figures assessing allosteric modulation,
underlying direct gating effects were subtracted out for calculation of summary data. Each
data point represents the mean ± S.E.M. of a minimum of 4 cells. *, p < 0.05; ***, p < 0.001.
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Figure 4. Assessment of direct gating effects of meprobamate in extrasynaptic GABA A
receptors. A, representative traces demonstrating meprobamate direct gating action on α4β3δ
and α1β3δ GABAA receptors, in comparison to a saturating concentration of GABA. The
maximal efficacy of meprobamate was comparable to that of GABA. B, Summary data
illustrating the efficacy of meprobamate compared to GABA in α1β2, α1β2γ2, α1β3δ and
α4β3δ GABAA receptor. Data for α1β2 and α1β2γ2 receptors are re-plotted from Figure 1 for
comparison. Efficacy of the full agonist THIP was also assessed; it was significantly more
efficacious than either GABA or meprobamate on δ-containing GABAA receptors. Each bar
represents the mean ± S.E.M. of a minimum of 3 cells for δ-containing receptors, and mean ±
S.E.M. of a minimum of 4 for all others. *, p < 0.05; **, p < 0.01.
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Figure 5. Assessment of allosteric effects of meprobamate in extrasynaptic receptors. A,
representative traces demonstrating the potentiation by meprobamate of GABA-gated (EC20)
currents in α4β3δ GABAA receptors. B, Bar graph summarizing the concentration-response
profile for the allosteric modulatory effects of meprobamate on extrasynaptic α4β3δ GABAA
receptors. Each bar represents the mean ± S.E.M. of a minimum of 3 cells.
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Figure 6. Potentiation of maximal GABA by meprobamate in extrasynaptic receptors.
A, Illustrative traces showing that in both α4β3δ and α1β3δ extrasynaptic GABAA receptors,
1 mM meprobamate significantly enhanced the magnitude of a saturating concentration of
GABA alone, whereas this potentiation was not observed in α1β3 or α1β2γ2 receptors.

B,

Summary data illustrating potentiation of maximal GABA current by both pentobarbital and
meprobamate in δ-subunit expressing receptors, compared to those not expressing the δ
subunit. Data are expressed relative to the peak current amplitude elicited by saturating
concentration of GABA. Each bar represents the mean ± S.E.M. of a minimum of 3 cells for
δ-containing receptors, and mean ± S.E.M. of a minimum of 4 for all others. **, p < 0.01.
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Figure 7. Assessment of “barbiturate-like” actions of meprobamate. A, top, representative
traces demonstrating meprobamate-activated currents are reversibly reduced in the presence of
the barbiturate antagonist bemegride in stably expressed human α1β2γ2 receptors. A, middle,
Neither pentobarbital nor meprobamate could directly gate wild type homomeric ρ1 receptors;
the W328M mutation conferred sensitivity to pentobarbital, but not meprobamate. A, bottom,
Pentobarbital directly gated homomeric 3 receptors, whereas meprobamate blocked the
spontaneously open current present in these channels. B, Summary results for experiments
presented in panel A. Each data point represents the mean ± S.E.M. of a minimum of 4 cells
for all data sets. *, p < 0.05; **, p < 0.01; ***, p < 0.001; #, p < 0.05 compared to the 3 mM
MEP effect, illustrating a concentration-dependent effect of bemegride.
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Abstract
Meprobamate (tradenames Miltown, Equanil) is a schedule IV anxiolytic and the primary
metabolite of the muscle relaxant carisoprodol. Though it used to be a widely prescribed
tranquilizer, a thorough understanding of its direct-gating, allosteric-modulation and inhibitory
effects remains ill-defined. Meprobamate modulates GABAA (γ-aminobutyric acid type A)
receptors, and has been described as having a barbiturate-like activity. In previous reports, we
found that in comparison to α1β2γ2 receptors, α3β2γ2 receptors had attenuated direct gating
effects for both meprobamate and carisoprodol. Here, using site-directed-mutagenesis and
whole cell patch clamp electrophysiology in transiently transfected HEK293 cells, we
examined the role of GABAA receptor α-subunit transmembrane domain 4 (TM4) amino acids
in direct gating actions of meprobamate, and transmembrane domain 2 (TM2) amino acids in
inhibitory actions of meprobamate and carisoprodol. Mutation of α3 valine at position t440 to
leucine (present in the equivalent position in the α1 subunit) increased the direct gating potency
and efficacy of meprobamate. In α1β2 heteromeric GABAA receptors, both pentobarbital and
carisoprodol had inhibitory effect for allosteric modulatory action at higher concentrations.
Meprobamate did not have an inhibitory effect at the concentrations tested. T6’F mutation of
the β2-subunit abolished the inhibition of carisoprodol but not of pentobarbital. Thus, our
studies provide further insight into molecular determinants of actions of meprobamate, its
parent drug carisoprodol and their comparison to barbiturate pentobarbital.
Key words: GABAA receptor; meprobamate; carisoprodol; muscle relaxant; drug abuse
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Introduction
GABAA receptors are members of cys-loop ligand-gated ion channel superfamily.
Other members of this group are glycine, acetylcholine receptor, GABAC receptors, serotonin
(5HT-3) receptors (Sine et al., 2006). GABAA receptors are the primary inhibitory receptors
of the CNS (Bormann, 2000). Upon activation, opening of chloride channels and chloride ion
entry, lead to the development of inhibitory post-synaptic potential (IPSP) (Bormann, 2000).
GABAA receptors are pentameric in nature. Each of the subunits are composed of a
long extracellular N-terminal domain, a short C-terminal domain, 4 transmembrane domains
(TM1-TM4), an extracellular TM2-TM3 loop and two intracellular loops, a large TM3-TM4
and a short TM1-TM2 loop (Cockcroft et al., 1995). TM2 of all the 5 subunits make the pore
of the channel (Xu et al., 1996; Miyazawa et al., 2003). Some inhibitors of GABAA receptors
interact with amino acids constituting TM2 loop (Gurley et al., 1995). GABAA receptors are
seats of action of many inhibitory ligands like benzodiazepines, barbiturates, neuro-steroids
and muscle relaxants like carisoprodol and meprobamate (Gonzalez et al., 2009b; Rudolph et
al., 2011; Kumar et al., 2015)
Meprobamate, used to be a widely prescribed tranquilizer, anti-convulsant and muscle
relaxant (Hendley et al., 1954; DeLong et al., 1985). Within few years of its introduction, cases
of abuse and physical and psychological dependence started piling up (Ewing et al., 1957). So
it was made a controlled substance (schedule IV) at the federal level. While meprobamate was
made a controlled substance, drugs metabolized to meprobamate are widely available. One
such drug is the muscle relaxant carisoprodol whose easy availability due to internet
pharmacies, has made it a widely abused drug (Toth et al., 2004; Sullivan, 2015). There have
been many cases of abuse, dependence and in some cases even death due to carisoprodol
toxicity (Adams et al., 1975; Elder, 1991; Littrell et al., 1993; Rust et al., 1993; Reeves et al.,
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2003; Zacny et al., 2011; Zacny et al., 2012). Although carisoprodol can have independent
action (Gonzalez et al., 2009b), a significant portion of its action and abuse is due to
meprobamate. As much of the research done on meprobamate has been in the years prior and
during its major use, its detailed mechanism of action is not clear. It was shown to act on
GABAA receptors in a barbiturate like manner (Rho et al., 1997). Our lab has shown
meprobamate to have both direct-gating and allosteric modulatory effect on all synaptic and
extra-synaptic GABAA receptors subunit combinations. For direct-gating, meprobamate and
carisoprodol, had maximum effect on α1 containing receptor while α3 had the least effect
(Kumar et al., 2015)(Kumar et al. 2016, in press). TM1-TM3 are fully conserved between α1
and α3 subunits. However, amino acids I419, I423 and V440 of TM4 of α3 are different from
that of α1 subunit (Barnard et al., 1998; Bergmann et al., 2013). Here we tested the hypothesis,
how this difference in the amino-acid compositions between α3 and α1 is responsible for the
difference in the direct gating actions on the two subunits.
High concentrations of carisoprodol and pentobarbital had inhibitory effects for
allosteric modulatory action in GABAA receptor. TM2 T6’ residue of the β-subunit of glycine
receptor, has been implicated in the blocking action of picrotoxin (Pribilla et al., 1992). Later
it was also shown to be critical in the picrotoxin blocking action in GABAA (Gurley et al.,
1995)and ρ1 GABAC receptors (Zhang et al., 1995). T6’F mutation has been known to cause a
significant reduction in picrotoxin inhibitory effect without abolishing it completely (Shan et
al., 2001; Sedelnikova et al., 2006). This residue has been shown to be involved in blocking
effects of other ligands of GABAA receptors. We tested the hypothesis that T6’ residue is also
implicated in the blocking action of carisoprodol and pentobarbital.
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2. Materials and Methods
2.1 Cell Culture and Transfection
Human embryonic kidney 293 (HEK293) cells transiently expressing varying GABAA
receptor subunits, were used in the present study. For transient transfection, cells were
transfected with human GABAA α; human β; and human γ2s (short isoform) cDNA in a 1:1:5
ratio (2 µg total cDNA) using PolyJetTM in vitro transfection reagent (SignaGen Laboratories,
Jamesville, MD). The γ2s subunit will be referred to as γ2 from here forth. Human GABAA
α1 subunit cDNA was generously provided by Neil Harrison (Columbia University Medical
Center, New York). Rat α1 and β2 subunits were also used. Transfection using just the α and
β subunits were made using the plasmids in ratio 1:1 with a total of 2µg of cDNA. PolyJet TM
in vitro transfection reagent was used 3µl/µg of DNA. Cells were plated on glass coverslips
coated with poly-L-lysine in 35-mm culture dishes, and maintained at 37ᵒC in a humidified
incubator with an atmosphere of 5% CO2 In all cases, cells were used for recording 24-72
hours after transfection.

2.2 Electrophysiology
Whole-cell patch clamp electrophysiology was used to assess GABA-, meprobamateor pentobarbital-activated Cl- currents. All electrophysiology experiments were conducted at
room temperature (22-25 ᵒC) with the membrane potential clamped at -60 mV. Patch pipettes
of borosilicate glass (1B150F; World Precision Instruments, Inc., Sarasota, FL) were pulled
(Flaming/Brown, P-87/PC; Sutter Instrument Company, Novato, CA) to a tip resistance of 4–
6MΩ. Patch pipettes were filled with a solution consisting of 140 mM CsCl, 10 mM EGTANa+, 10 mM HEPES-Na+, and 4 mM Mg2+-ATP, pH 7.2. Coverslips containing cultured cells
were placed in the recording chamber on the stage of an inverted light microscope and
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superfused continuously with an external solution consisting of 125 mM NaCl, 20 mM HEPES,
3 mM CaCl2, 5.5 mM KCl, 0.8 mM MgCl2, and 10 mM glucose, pH 7.3. Agonist-induced Cl−
currents were obtained with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA)
equipped with a CV-203BU headstage. Currents were low-pass filtered at 5 kHz, monitored
simultaneously on an oscilloscope and a chart recorder (Gould TA240; Gould Instrument
Systems Inc., Cleveland, OH), and stored on a computer using an on-line data acquisition
system (pCLAMP 6.0; Axon Instruments) for subsequent off-line analysis.

2.3 Chemicals and solutions
Meprobamate, carisoprodol, pentobarbital, diazepam, salts and buffers were purchased
from Sigma Aldrich (St. Louis, MO). GABA was obtained from Acros Organics (New Jersey,
US). Stock solutions of meprobamate, pentobarbital and carisoprodol were made using
dimethylsulfoxide (DMSO). Drugs were diluted in normal saline, so that the final DMSO
concentration (vol/vol) of the test solutions was ≤0.3%. GABA and diazepam stock solutions
were prepared using de-ionized H2O.

All stock solutions were stored at -20 ᵒC. On

experimental days, drug-containing solutions were prepared from stock by serial dilution into
external solution.

2.4 Experimental Protocol
GABA (with or without modulatory ligand), meprobamate, carisoprodol or
pentobarbital were prepared in external solution on the day of use and applied via a 16-barrel
rapid perfusion system in which all barrels (200 µm outer diameter quartz tubes; ALA
Scientific, Folsom, CA) emptied via a common tip positioned adjacent to the cell under study.
Flow through each barrel was pressure fed and regulated by solenoid or pinch valves operated
by a programmable microprocessor-based controller. Only one valve was open at a time, and
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the buffer solution was applied continuously between drug applications via gravity or positive
pressure. For some experiments, ligands were applied via gravity flow using a Y-tube placed
adjacent to the cell.
The modulatory effects of meprobamate, pentobarbital or carisoprodol on GABAgated currents were assessed using an EC20 gating concentration of GABA as the control. This
gating concentration was selected to ensure there was a sufficient range to observe the full
allosteric potential of meprobamate. To ensure the gating concentration was approximately an
EC20, control responses were compared to the maximal GABA-gated current for each
individual cell. On a cell by cell basis, control GABA currents were deemed acceptable for
assessment of allosteric modulatory effects of meprobamate if they were within a 15-25 %
range of maximal current for that particular cell. Control responses were established by
observing two consecutive agonist-activated currents that varied in amplitude by no more than
± 10%. In our analyses of the modulatory effects of meprobamate, peak current amplitude was
defined as the maximum current elicited by GABA. In all studies assessing direct gating
effects, the magnitude of the response was expressed relative to the maximal effect of GABA
(designated 100%). For αβγ configurations, GABA-gated control currents were recorded in
the presence of diazepam to confirm incorporation of the γ2 subunit.

2.5 Data Analysis
To ensure equipotent concentrations were used for gating, GABA concentrationresponse data were collected. From these data, EC20 and saturating GABA concentrations were
calculated for each configuration and used in subsequent investigations of the allosteric and
direct effects, respectively. For studies assessing allosteric actions, a correction was applied
to subtract underlying direct gating effects. All data are presented as mean values ± S.E.
Statistical significance (p<0.05) between control and test conditions was determined using
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Student’s t-test (paired or unpaired) and one-way analysis of variance. Tukey-Kramer post hoc
test for multiple comparisons was performed as needed.

2.6 Plasmids and site-directed-mutagenesis
Human cDNA plasmids encoding α1, α3, β2 and γ2 GABAA receptor subunits were
used in the present study. Individual and combined mutations in α3 cDNA plasmids were
created using Stratagene’s Quik Change II ® site-directed-mutagenesis kit (Agilent
Technologies; La Jolla, CA) and were sequenced to confirm mutations at West Virginia
University’s Genomics Core Facility.
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3. Results

3.1 TM4 amino acid mutations α3 to corresponding α1, lead to an increased meprobamate
mediated direct gating effect
On testing for the action of meprobamate on various subunit compositions of GABAA
receptors, we found it to have maximum direct-gating effect on α1 and a significantly
attenuated effect on α3 containing GABAA receptors. Further we saw the effect of
meprobamate to be consistent with its action in the transmembrane region (Hosie et al., 2006).
When we looked for difference in structure, amino-acid compositions of TM1-TM3 regions is
conserved between α1 and α3 subunit isoforms. TM4 region is also largely conserved, except
for, I420, I424 and V441 of α3, which differs from α1, which are L420, A424 and L441
(Barnard et al., 1998; Bergmann et al., 2013) (Fig.1). To test the roles of these amino acids
unique to α3 in the attenuated direct gating effect, successive mutations were made to convert
α3 to α1 either singly or in combination, using site directed mutagenesis. Mutations tested
were, α3 (V441L), α3 (I420L/I424A) and α3 (I420L/I424A/ V441L). In order to assess the
receptor function, GABA concentration response was done on each mutants. In general, the
shift in GABA EC50 was modest (Table 1). We observed an increase in direct gating efficacy
for meprobamate in mutant receptors compared to WT α3 receptors, suggesting the role of
above amino acids in different direct gating efficacy of α3 and α1 receptors.

3.2 Carisoprodol and pentobarbital, but not meprobamate show an inhibition and rebound at
high concentrations in WT α1β2 GABAA receptors
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At lower concentrations (< 100 µM), pentobarb, meprobamate and carisoprodol
enhanced GABA mediated current in a concentration-dependent manner. At higher
concentrations (> 100 µM), there was successive attenuation of GABA-mediated current by
both pentobarb and carisoprodol. At 3 mM a rebound or offshoot was observed on drug
application termination (Fig 3A and 4A). Neither an attenuation nor rebound was observed
with meprobamate at the concentrations tested (till 3 mM) (Fig. 5A). We may observe a similar
effect for meprobamate at higher concentrations as it has shown approximately 3 times less
sensitivity than carisoprodol in our previous reports.

3.3 T6’F mutation in β2 subunit, attenuates inhibition and rebound (offshoot) currents in
carisoprodol, but not in pentobarital
Lower concentration of both pentobarb and carisoprodol enhanced GABA-mediated
currents in WT α1β2 GABAA receptor. At concentrations > 100µM, there was progressive
inhibition and a rebound and offshoot was observed upon drug termination at 3 mM with both
the ligands. A T6’ amino-acid in the β2 subunit has previously been implicated in inhibitory
effects of other inhibitory ligands. TM2 T6’ residue of the β-subunit of glycine receptor, has
been implicated in the blocking action of picrotoxin (Pribilla et al., 1992). Later it was also
shown to be critical in the picrotoxin blocking action in GABAA receptor (Gurley et al., 1995)
and ρ1 GABAC receptor (Zhang et al., 1995). T6’F mutation was tested since it has been known
to cause a significant reduction in picrotoxin sensitivity without abolishing it completely (Shan
et al., 2001; Sedelnikova et al., 2006). We tested the hypothesis that T6’ residue is implicated
in the above blocking actions. TM2 T6’ residue, when mutated to T6’F, both inhibition and
rebound mediated by carisoprodol, was attenuated. No effect was observed on pentobarb
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mediated inhibition or rebound. Thus, pentobarbital may have different binding site or
functional domain for this particular action. Pentobarbital had a direct gating effect in β3
homomeric receptors. Both meprobamate and carisoprodol, like picrotoxin, blocked
spontaneously open current in the β3 homomer. This MEP and CSP mediated blockage was
abolished in homomer with T6’F mutation, unmasking their direct gating effect. Homomer
with T6’F mutation in β3 subunit, did not affect pentobarbital mediated direct gating current,
again suggesting a different binding site or a functional domain for this particular action.
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4. Discussion
Meprobamate was the first widely prescribed tranquilizer agent (DeLong et al., 1985).
Initially found to be free of side effects in animal studies and in populations using regular
therapeutic doses (Boyd et al., 1958), many cases of abuse and dependence were observed in
patients having history of misuse of other drugs and alcohol abuse (Mohr et al., 1958). Also,
after long term use, cases of physical and psychological dependence started to appear (Lemere,
1956; Ewing et al., 1957). Thus, it was made a controlled substance and its use started to
dwindle after the introduction of benzodiazepines (Berger, 1964; Greenblatt et al., 1974).
Although meprobamate was made a controlled substance, drugs metabolized to meprobamate
are widely available. One such drug is the centrally acting muscle relaxant carisoprodol (Toth
et al., 2004; Sullivan, 2015). It is easily available and widely used, especially after the advent
of internet pharmacies. Many serious cases of abuse, dependence and withdrawal have also
been reported for carisoprodol (Adams et al., 1975; Elder, 1991; Littrell et al., 1993; Rust et
al., 1993; Reeves et al., 2003; Zacny et al., 2011; Zacny et al., 2012). Carisoprodol was known
to act via its metabolite meprobamate, already a controlled substance and without a known
mechanism of action. Our previous reports have shown carisoprodol itself, independent of
meprobamate, and meprobamate act on synaptic and extra-synaptic GABAA receptor in a
subunit dependent manner (Gonzalez et al., 2009b; Kumar et al., 2015). For direct-gating
actions, meprobamate potency and potentially efficacy, was much higher for α1 expressing
GABAA receptor compared to α3 expressing GABAA receptor. In this respect, action of
meprobamate is qualitatively similar to its parent drug carisoprodol, however, the potency of
this effect is lot less for meprobamate compared to carisoprodol (Gonzalez et al., 2009b; Kumar
et al., 2015) (Kumar et al. 2015, in press).
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Activity of meprobamate and carisoprodol suggest a transmembrane-domain specific
action (Hosie et al., 2006). Upon alignment, there is similar amino-acid compositions in the
TM1-TM3 region, while TM4 region has 3 different amino-acid composition between α1 and
α3 subunits. These were I419, I423 and V440 (Barnard et al., 1998; Bergmann et al., 2013).
To test their role in attenuated direct gating effects of meprobamate at α3, we tested successive
mutations from α3 to α1 subunit. An increase in direct gating efficacy was observed, suggesting
the role of these amino acids for the direct-gating actions of meprobamate. A similar gain in
function was also observed for carisoprodol, though of a much higher magnitude. This shows
similar domains may be responsible for the direct-gating actions of carisoprodol and
meprobamate.
Further, meprobamate and carisoprodol actions have been described as barbiturate like
(Rho et al., 1997; Gonzalez et al., 2009b). In our previous reports, we have seen several points
of similarities and differences in the actions of meprobamate, carisoprodol and barbiturates.
Supra-potentiation of GABA saturation current seen in δ-containing GABAA receptors was
also observed with carisoprodol and meprobamate. Mice trained to identify carisoprodol also
identified meprobamate and pentobarbital. Barbiturate-antagonist, bemegride, reversibly
inhibited meprobamate and carisoprodol mediated currents (Gonzalez et al., 2009b)(Kumar et
al., 2015, in press). Also in ρ1-homomeric receptor, natively found in retina, meprobamate,
carisoprodol and barbiturate pentobarbital, did not have any direct effect. However, a W328M
mutation in ρ1, salvaged pentobarbital mediated current, but not that of carisoprodol and
meprobamate (Gonzalez et al., 2009b)(Kumar et al., 2015, in press). Also in β3 homomeric
receptors pentobarbital had a direct-gating action whereas meprobamate had an inhibitory
action similar to picrotoxin.
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In this study we used α1β2 hetero-pentamer to test for inhibitory actions of
carisoprodol, meprobamate and pentobarbital. At lower concentrations (< 100 µM), all three
enhanced GABA mediated current. However at higher concentrations, an inhibition was
observed with pentobarbital and carisoprodol. At 3 mM, a rebound current was observed upon
termination of both pentobarbital and carisoprodol. Meprobamate continued to enhance GABA
mediated current at concentrations tested (3mM). One reason could be the lower sensitivity of
meprobamate compared to carisoprodol (approximately one third of carisoprodol). We may
see a similar phenomenon at higher concentrations. T6’ of β2 is found in the TM2 region (pore
region) and has been implicated in the inhibitory effect of picrotoxin (Pribilla et al., 1992;
Gurley et al., 1995; Zhang et al., 1995). We tested whether this amino acid is responsible for
the inhibitory effects observed with the two ligands as T6’F mutation has been shown to abolish
picrotoxin mediated inhibition (Shan et al., 2001; Sedelnikova et al., 2006). T6’, mutated to
T6’F, abolished the inhibitory and rebound effects of carisoprodol but not of pentobarbital.
This suggests T6’ residue responsible for the inhibitory effect of carisoprodol but not of
pentobarbital. At the concentrations tested, meprobamate did not show an inhibitory effect.
Taken together these findings suggest a distinct sight for inhibitory actions for barbiturates
compared to carisoprodol and meprobamate.
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Table III-1. Influence of GABAA receptor α3 TM4 amino acids mutation to
corresponding α1 amino acids on GABA EC50 values Each data point represents the mean
± S.E.M of n cells. *, p < 0.05; **, p < 0.01 relative to wild type α3β2γ2 GABAA receptors.
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Receptor
Configuration

MEP gating

GABA
n

(% of GABA
max)

n

EC50 (µM)

α3 WT

34.8 ± 2.1

6

7.25 ± 2.8

5

α3(V440L)

07.5 ± 0.9 **

7

13.25 ± 1.89

3

α3(I419L/I423A)

18.1 ± 2.2*

9

12 ± 4

3

α3(I419L/I423A/V440L)

15.8 ± 5.0 *

6

8 ± 2.65

3

α1 WT

28.6 ± 2.75

8

32 ± 8.1

5
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Figure 1. Alignment of α1 and α3 domains of TM4 showing non-identical (red) and mutated
(*) amino acids. Conserved (black).
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Figure 2. Influence of the alpha3 subunit TM4 mutations on direct activation by
meprobamate. A, representative traces demonstrating carisoprodol and meprobamate activate
human 3(V441L) 22 GABAARs. B, bar graphs summarizing meprobamate direct gating
currents for human α3-, α3 (V441L)-, α3 (I420L/I424A/V441L) and 122 GABAARs. **,
p< 0.01, *, p< 0.05.

MT1 - α3 (V441L); MT2 - α3 (I420L/I424A) and MT3 - α3

(I420L/I424A/ V441L).
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Figure 3. Influence of β-subunit TM2 T6’F Mutation on inhibitory effects of carisoprodol.
A) Representative traces from R-α1β2 GABAA receptor demonstrating modulation of GABAgated currents by carisoprodol. At high concentrations, currents are inhibited and offshoot
currents are observed upon termination of drug application. This phenomenon is attenuated
with α1β2 (T6’F) GABAA receptor. B) Low concentration CSP potentiated the GABA gated
current of both R-α1β2 GABAA receptor and R-α1β2 (T6’F) GABAA receptor. High
concentration of CSP inhibit R-α1β2 receptors but in R-α1β2 (T6’F) receptors, inhibitory effect
was attenuated. Each bar represents the mean ± S.E. of the 7-9 cells.
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Figure 4. Influence of β-subunit TM2 T6’F Mutation on inhibitory effect by
pentobarbitol. A) Representative traces from R-α1β2 GABAA receptor demonstrating
modulation of GABA-gated currents by pentobarbital. At high concentrations, currents are
inhibited and offshoot currents are observed upon termination of drug application. A similar
phenomenon is observed with α1β2 (T6’F) GABAA receptor. B) Low concentration PB
potentiated the GABA gated current of both R-α1β2 GABAA receptor and R-α1β2(T6’F)
GABAA receptor. High concentration of PB inhibit R- α1β2 receptors but in R-α1β2(T6’F)
receptors, inhibitory effect was not attenuated unlike CSP. Each bar represents the mean ± S.E.
of the 7-8 cells.
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Figure 5. Influence of β-subunit TM2 T6’F Mutation on allosteric modulation by MEP.
A) Representative traces from R-α1β2 GABAA receptor demonstrating modulation of GABAgated currents by MEP. At high concentrations, no offshoot currents are observed upon
termination of drug application and currents are not inhibited as seen with CSP or PB. A similar
phenomenon is observed with α1β2 (T6’F) GABAA receptor. B) Low concentration MEP
potentiated the GABA gated current of both R-α1β2 GABAA receptor and R-α1β2 (T6’F)
GABAA receptor. High concentrations of MEP do not inhibit R-α1β2 or R-α1β2 (T6’F)
receptors. Each bar represents the mean ± S.E. of the 7-8 cells.
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SUMMARY, DISCUSSION AND FUTURE DIRECTIONS
Meprobamate was the first drug to be prescribed purely as a tranquillizer, that is,
capable of allaying anxiety without inducing sedation or sleep (DeLong et al., 1985). It was a
wonder drug when introduced and sold billions of pills. With therapeutic doses, it did not
produce addiction or dependence, even after prolonged use (Boyd et al., 1958). Higher than
normal dose, in patients with history of other drugs or alcohol abuse, led to all the
characteristics of a habit forming drug. These include an intense craving for the drug based on
its euphoric effect, tolerance build up, requiring increasingly larger doses to produce the same
effect, and withdrawal symptoms associated with sudden discontinuation of the drug (Lemere,
1956; Mohr et al., 1958). Considering increasing number of cases of physical and
psychological dependence, meprobamate was made a controlled substance (Greenblatt et al.,
1971; Hollister, 1983). While meprobamate is a controlled substance, drugs metabolized to
meprobamate are widely and easily available, and abused. One such drug, carisoprodol, is a
widely prescribed centrally acting skeletal muscle relaxant (Toth et al., 2004; Sullivan, 2015).
It is most commonly used for short term allaying of skeletal muscle pain and discomfort.
Carisoprodol use has been characterized by quick development of tolerance, leading to use of
increasing doses to produce the desired effect. After long term use of high dose of carisoprodol,
strong withdrawal symptoms have been observed. These include delusion, seizure and even
death (Adams et al., 1975; Elder, 1991; Littrell et al., 1993; Rust et al., 1993; Reeves et al.,
2003; Zacny et al., 2011; Zacny et al., 2012). Considering the dangers posed by the abuse of
carisoprodol, it was made a scheduled 4 controlled substance at the federal level in January
2012 by the United States Drug Enforcement Administration. Considering present and
potential danger posed by carisoprodol use and abuse, it was of utmost importance to know its
detailed mechanism of action. For long it was known to act via its metabolite meprobamate,
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which lacks the isopropyl group found in carisoprodol. Meprobamate is already a controlled
substance, but its detailed mechanism of action is also unknown.
It has been shown that the therapeutic and adverse effects of GABA ligands depend
upon their interactions with the GABAA receptor subunits (Ito et al., 1996; Ator, 2005; Licata
et al., 2005; Wafford, 2005; Olsen et al., 2008). α2 containing GABAA receptors have the
anxiolytic and, to a large extent, myorelaxant actions; and the α3- and α5-containing GABAA
receptors, have the myorelaxant actions. Moreover, tolerance to the sedative action has been
linked to α5-containing GABAA receptors, and their addictive properties to α1-containing
GABAA receptors (Low et al., 2000; McKernan et al., 2000; Crestani et al., 2001; Crestani et
al., 2002; Rudolph et al., 2004; van Rijnsoever et al., 2004; Tan et al., 2010). In addition,
physical dependence is more likely to develop with drugs that interact with a broader collection
of GABAA receptor subtypes and misuse of agents that directly gate the receptor is more likely
to result in fatal complications than those that only allosterically enhance receptor activity
(Licata et al., 2008; Fass, 2010). So we tested for detailed subunit dependent action of
carisoprodol on GABAA receptor, but in order to understand a complete pharmacological
profile of this widely used and abused drug, we also set out to understand the complete subunit
dependent action of its metabolite, meprobamate. The only knowledge regarding the action of
meprobamate was its interaction in a barbiturate like manner with GABAA receptors. So, we
also set out to chalk out the difference between the action of meprobamate and barbiturate
pentobarbital.
We found meprobamate to have direct gating, allosteric modulatory and inhibitory
actions on various synaptic and extra-synaptic GABAA receptors. For direct gating, α1 had
significantly more efficacy than α3 containing receptors. To understand the molecular basis for
the difference, amino-acid compositions of the α3 and α1-subunits were aligned. We identified
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several amino-acids of difference between the two subunits in the TM4 region. Using site
directed mutagenesis, amino-acids from α3 were converted to those in α1 either singly or in
combination. We found a gain in function, suggesting these amino-acids to be responsible for
attenuated α3 direct gating action. A similar gain in function was also observed for
carisoprodol, however of a much higher magnitude. Structural difference between carisoprodol
and meprobamate is minimal. Both are propanediol bicarbamate, with carisoprodol having an
isopropyl group, absent in meprobamate.
For allosteric modulatory action of meprobamate, α5 subunit was somewhat more
efficaceous compared to other subunits. In carisoprodol, α1 subunit was significantly more
potent and efficacious than other subunits. Also, carisoprodol potency on all the subunits, was
more than meprobamate. So for allosteric-modulatory actions, a difference in potency and
subunit preferring effect was observed.
Effects of β and γ subunits were also tested for direct gating and allosteric modulatory
effects. γ subunit did not have any influence on both these effects of carisoprodol. While for
meprobamate, γ subunit did not influence the direct gating but had a significant inhibitory
effect for allosteric-modulation. β subunit had an effect on both the direct gating and allosteric
modulation of carisoprodol. β1 subunit had significantly more direct-gating effect compared
to β2 while β2 had significantly more allosteric-modulatory effect compared to β1. β-subunit
did not influence either meprobamate direct gating or allosteric modulation. The above
differences may be exploited to know about the critical domains responsible for the action of
meprobamate and carisoprodol.
Extra-synaptic GABAA receptors represented by α4β3δ and α1β3δ were also tested.
Both meprobamate and carisoprodol had a supra-potentiation effect on GABA saturation. In
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this respect, actions of both carisoprodol and meprobamate were barbiturate like. For direct
gating action on the extra-synaptic receptors, both carisoprodol and meprobamate were almost
as much efficacious as GABA. Both meprobamate and carisoprodol also had allostericmodulatory effects on the extra-synaptic receptors.
Further comparison with the barbiturates was done using ρ1 homomeric receptors
found natively in retinal ganglion cells and β3 homomeric receptors, not found natively. All
three, meprobamate, carisoprodol and pentobarbital did not have a direct gating action on ρ1homomeric receptors. A mutation W328M, however, salvaged the direct gating action of
pentobarbital, but not of carisoprodol or meprobamate. For β3-homomeric GABAA receptors,
barbiturate pentobarbital had an agonist effect while meprobamate, blocked the spontaneously
open current, a mechanism followed by picrotoxin, a known GABA inhibitor. A T6’F mutation
in β3 subunit abolished the meprobamate mediated inhibition, without affecting the
pentobarbital mediated direct gating.
In receptors formed by α1β2, allosteric actions of meprobamate, carisoprodol and
pentobarbital were tested. Meprobamate, at tested concentrations (maximum 3 mM),
continuously potentiated GABA mediated current in a concentration dependent manner. At
lower concentrations (< 100µM), carisoprodol and pentobarbital potentiated GABA gated
currents in a concentration dependent manner but at higher doses, showed an inhibition and a
rebound at 3mM. T6’ residue in β-subunit TM2 region (pore forming region) when mutated to
T6’F, attenuates the inhibition and abolishes the rebound in carisoprodol, but not pentobarbital.
Thus 6’ residue seems to be involved in the inhibitory actions of carisoprodol, but not
pentobarbital. At concentrations tested, meprobamate did not show an inhibitory action in α1β2
receptors. Meprobamate may show an inhibitory and rebound effect on testing at higher
concentration as it has shown to be approximately 3 times less sensitive than carisoprodol, in
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our previous reports. In β3 homomeric receptor both meprobamate and carisoprodol block
spontaneously open current. A T6’F mutation abolishes this action for both carisoprodol and
meprobamate and unmask their direct gating effect. So the β3 actions represent a similarity
of action of meprobamate and carisoprodol, representing a similar binding site/or functional
domain for this particular action, between carisoprodol and meprobamate. Pentobarb has an
agonist action at β3 homomeric receptors representing a different binding site/functional
domain than both meprobamate and carisoprodol.
In an effort towards drug development, we need to further explore the mechanism of
actions of meprobamate. We saw a gain in function for the direct action from α3 to α1
conversion mutations in the TM4 region. We need to test the same for the reverse mutations
from α1 to α3 and observe whether there is a loss of function. A similar study conducted for
carisoprodol, showed leucine residue at position 415 of α1 subunit to be responsible for its
direct gating action. The combination of the above two studies would help us to identify the
amino acids responsible for the direct gating actions of the meprobamate.
An important study would be to identify the property of the amino-acids responsible
for the direct gating action. For this, amino-acid identified for the direct gating action shall be
mutated to various other amino acids with varying size, charge, hydrophoebicity or polarity. A
correlation observed between the magnitude of the current and a particular property would help
us identify that particular property to be responsible for the direct gating. For carisoprodol, at
position 415, volume and polarity of the amino acids have been shown to be associated with
its direct gating efficacy. A similar study shall be undertaken to find the binding domain and
property of the amino acids responsible for the allosteric modulation. Above amino acids did
not seem to have an effect on the allosteric modulatory effect of carisoprodol. For further
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understanding of the domains responsible for the binding pocket for direct gating and allosteric
modulatory action, we shall also take resort to molecular modeling techniques.
Further, allosteric modulatory actions of general anesthetics etomidate, propofol and
isoflurane have shown voltage dependence (O'Toole et al., 2012). Parent drug of meprobamate,
carisoprodol has also shown voltage dependent allosteric modulatory actions but not direct
gating action (Kumar et al., 2015). Again showing a different binding sites for carisoprodol for
direct gating and allosteric modulatory effects and thus multiple binding sites for carisoprodol
at GABAA receptor. It would be interesting to see whether meprobamate mediated actions also
show voltage dependence.
We are still not sure whether the amino acid identified via the mutation studies
participate in the direct binding or carry the wave of conformational changes, a mechanism
called coupling. Substituted cysteine accessibility method would help us to differentiate
between the two. The substituted-cysteine accessibility method (SCAM) provides an approach
for identifying the amino acid residues that line channels , transporters, or binding-site crevices
in membrane-spanning proteins (Chen et al., 1997; Javitch et al., 1998; Dodd et al., 2005).
SCAM can also be used to investigate structural alterations in membrane-spanning segments
in different functional states of proteins. Sulfhydryl group of native or engineered cysteine of
a protein can be at water accessible surface, lipid accessible surface or a protein interior. Rate
of reaction of a hydrophilic reagent would be much faster with an ionized sulfhydryl group (at
water accessible region) than a non ionized sulfhydryl group. Measuring the rate of change of
reaction of an engineered cysteine with a hydrophilic reagent in presence or absence of a ligand
can help us conclude the movement of the particular amino acid (and thus the loop) in presence
of the ligand and thus its participation in the gating process of a ligand.
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It has become increasingly clear in recent years that many therapeutic and adverse
actions of GABAergic drugs associate predominantly with particular subunits of the GABA A
receptor. This has been studied extensively in animal models in which a particular subunit is
deleted and resultant absence of a particular effect is attributed to the deleted subunit. This
technique has been used to show the subunits responsible for alcohol tolerance, dependence,
consumption and taste aversion (Barnard et al., 1998; Jacob et al., 2008; Miller et al., 2014;
Whissell et al., 2015). A role for extrasynaptic receptors have also been attributed for alcohol
consumption using similar techniques (Feusner et al., 2001). Knockout mice have also been
used for assessing therapeutic and abuse potentials for benzodiazepines (Rudolph et al., 2011).
Our study demonstrates that meprobamate action in-vitro depends upon GABAA receptor
subtype isoforms. A further testing of our findings in in-vivo model in the knockout mice would
further confirm actions of meprobamate on the tested subunits and help us better predict subunit
dependent effects of meprobamate.
Meprobamate has both tranquilizing and muscle relaxing properties. An initial effort was
made by Berger for preparation of compounds for the separation of the above two activities. In
this effort many compounds chemically related to meprobamate were prepared and subjected
to pharmacological evaluation (Berger et al., 1960). From the chemical formula of
meprobamate, 2-methyl-2-propyl-1, 3-propanediol dicarbamate, the N-substituted and Nnonsubstituted compounds were tested for muscle relaxant, anti-convulsant and toxic actions.
N-isopropyl-2-methyl-2-propyl-1, 3-propanediol dicarbamate, or carisoprodol showed a
promising muscle relaxant action alienated from tranquilizing action of meprobamate (Berger
et al., 1960). Carisoprodol was further tested and made available for medical use. One reason
CSP was further evaluated was its proximity to the structure of meprobamate which was widely
used at that time and thus had a proven safety profile. Also with the cost of further evaluation,
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not many compounds could have been tested at that time. However many compounds generated
showed a promising muscle relaxant and anti-convulsant profile. Chemical groups commonly
tested were 3-propanediols; 1, 3-propanediol bicarbamates and 3-hydroxypropyl carbamates
(Figure 1) (Ludwig et al., 1969).
Compounds of interest were 2-substituted 1, 3-propanediol bicarbamates. A total of 5-7
carbon atoms at the 2-position had the greatest muscle relaxing properties. An aryl group
reduces muscle relaxing properties, while a methyl and a phenyl group has an enhanced anticonvulsant activity and reduced muscle relaxing properties. N-Substituted compounds have
also shown interesting properties. Replacement of one of N-hydrogen of the carbamate has
yielded a number of compounds with interesting muscle relaxing properties. A prominent
example is widely prescribed muscle relaxant carisoprodol or N-isopropyl-2-methyl-2-propyl1, 3-propanediol dicarbamate (Ludwig et al., 1969).
2-Substituted and N-substituted 3-hydroxypropyl carbamate, also show prominent
muscle relaxing and anti-convulsant properties. 4-5 alkyl groups at position 2 gave good
muscle relaxing property while an aromatic group at this position had good anti-convulsant
property and attenuated muscle relaxant property. N-Substituted compounds also had
prominent muscle relaxant and anti-convulsant compounds (Ludwig et al., 1969).
Our lab provides low cost methods for further evaluation of these drugs. A testing at
GABAA subunits would enable us to have a quick prediction of therapeutic and abuse potentials
of these drugs. We would start by generation of as many of the above promising ligands as
possible. Each of the ligand would be tested for direct gating and allosteric modulatory effects
at various α and β subunit combinations of the GABAA receptors. Thus a pharmacologic profile
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of each ligand would be generated, along with a note on possible therapeutic as well as abuse
potentials of each ligand. Promising ligands would be further tested in animal models.
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Figure 1: Chemical structure of meprobamate; 1,3 propanediol; 3-hydroxypropyl carbamate
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In between carisoprodol and meprobamate, they have global effect on various subunit
combinations of synaptic and extra-synaptic GABAA receptors. In addition to having effects
on GABA mediated currents, they also have a direct-gating actions on all these native
receptors. Meprobamate have also been shown to have partial inhibitory effect on NMDA
receptors (Rho et al., 1997). In our lab and our colleague’s, we have shown carisoprodol also
to have partial inhibitory effect on NMDA receptors, both in vitro in HEK-t transfected cells,
as well as in animals trained to identify carisoprodol. Further clinical effects of carisoprodol
also seem to affect serotonergic receptors (Bramness et al., 2005). Both the actions of
carisoprodol and meprobamate on NMDA and 5 HT-3 receptors need to be further explored.
Our knowledge of qualitative and quantitative aspects of effects of meprobamate and
carisoprodol on various subunits of synaptic and extra-synaptic GABAA receptors, have
enabled us to explain molecular basis of various clinical and toxic effects observed with the
use and abuse of these drugs. Further research on the molecular mechanism of actions of these
drugs (further exploration on GABAA receptors, NMDA and 5HT-3 receptors), would not only
explain the clinical effects observed, but may also enable us to bring these drugs for new uses
in select group of patients with specific needs. Our studies in lab could also prove to be
important for drug development, as molecules with induced structural changes to have desired
properties, can be quickly tested in cellular models, rather than time taking and costly animal
models used in the initial development of these drugs. MEP and CSP would prove to be
important drugs for blanket testing of reagents for a particularly useful action at an unknown
potential therapeutic site of action or interaction with useful enzymes. Like amantadine, an
anti-influenza drug also used as an anti-parkinsonism drug, their global action on receptors
with varying physiological actions may prove to be an important property to test for actions on
unknown useful sites.
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